Radiotherapy Supports Tumor Specific Immunity by Acute Inflammation by Surace, Laura
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2015
Radiotherapy Supports Tumor Specific Immunity by Acute Inflammation
Surace, Laura
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-136838
Originally published at:
Surace, Laura. Radiotherapy Supports Tumor Specific Immunity by Acute Inflammation. 2015, Univer-
sity of Zurich, Faculty of Science.
Radiotherapy Supports Tumor Specific Immunity by Acute 
Inflammation 
 
 
 
Dissertation 
 
 
 
 
zur 
Erlangung der naturwissenschaftlichen Doktorwürde 
(Dr. sc. nat.) 
 
 
vorgelegt der 
Mathematisch-naturwissenschaftlichen Fakultät 
der  Universität Zürich 
 
 
 
 von 
Laura Alba Maria Surace 
aus 
Italy 
 
 
 
Promotionskomitee 
 
Prof. Dr. Maries van den Broek (Leitung der Dissertation & Vorsitz) 
Prof. Dr. Burkhard Becher 
Prof. Dr. Sabine Werner 
Prof. Dr. Martin Pruschy 
 
 
 
 
Zürich, 2015 
	 2 
List of content 
 
Summary          3 
Zusammenfassung         4 
Introduction          5 
1. The immune system        5 
  1.1 Lymphoid organs        5 
  1.2 General aspects of the immune system      5 
  1.3 Innate immunity         6 
  1.4 Adaptive immunity        7 
     1.4.1 Lymphocytes development       7 
     1.4.2 B cells         8 
     1.4.3 T cells         10 
2. The immune response        13 
  2.1 Antigen presentation and antigen-presenting cells    13 
  2.2 T cell fates: priming, peripheral tolerance and exhaustion   15 
  2.3 The complement system: a bridge between innate and adaptive  
        immune response        19 
3. Tumor immunology        21 
  3.1 Immunity against cancer        21 
  3.2 The major stumble stones for immunity against cancer    23 
  3.3 Exploiting the immune system to control cancer    24 
4. Radiotherapy         27 
  4.1 Radiotherapy induces lethal DNA damage     27 
  4.2 Radiotherapy stimulates tumor-specific immunity    29 
5. References          30 
Complement is a central mediator of radiotherapy-induced tumor-specfic    
immunity and clinical response       46 
Radiotherapy increases the functionality of lymphatic vessels without  
modifying their structure        71 
Discussion          85 
Curriculum Vitae         92 
Acknowledgements         94 
 
 
	 3 
 
 
Summary 
 
 
It is now well accepted that the immune system can control tumors. There is a positive correlation 
between tumor infiltration by effector T cells and survival, and the risk to develop cancer is 
increased in immunosuppressed patients. Despite the presence of tumor-specific immunity in many 
cancer patients, complete rejection is rare, presumably due to mechanisms that locally inhibit 
tumor-specific protective immunity.  
Along with surgery and chemotherapy, radiotherapy is an important treatment for cancer. 
Radiotherapy induces irreversible damage to DNA, thus targeting mainly rapidly dividing cells. 
Although radiotherapy was considered an immunosuppressive treatment, there is accumulating 
evidence that it supports local tumor-specific immunity and, in fact, that immune activation might 
be an integral part of radiotherapy.  
In the first part of this study we reported that radiotherapy transiently activated complement within 
the irradiated tissue resulting in local production of the anaphylatoxins C3a and C5a. 
Anaphylatoxis were crucial to maturation of radiotherapy-induced maturation of tumor-associated 
dendritic cells, T cell effector function and clinical efficacy. Our data suggest that radiotherapy 
induces a local and transient inflammatory response that supports tumor-specific immunity and of 
which complement is an essential component. In line with this, interference with the inflammatory 
response by dexamethasone, a corticosteroid often given to patients in the context of radiotherapy, 
reduced the efficacy of radiotherapy in a preclinical model. We thus propose that the acute 
inflammatory response that results from radiotherapy actually may contribute to its efficacy. 
In the second part of this study, we investigated the impact of radiotherapy on the structure and the 
function of tumor-associated lymphatic vessels. We observed that radiotherapy did not impact on 
the structure of lymphatic, but it seemed to enhance lymphatic drainage.  
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Zusammenfassung 
 
Dass das Immunsystem in der Lage ist, Tumore zu kontrollieren, ist heute eine akzeptierte 
Tatsache. Das Überleben von Krebspatienten korreliert positiv mit der Menge an Effektor T-
Zellen, die in den Tumor einwandern. Ausserdem ist das Risiko an Krebs zu erkranken bei 
immunsupprimierten Patienten wesentlich höher als bei solchen mit intaktem Immunsystem. Trotz 
des Vorhandenseins von tumorspezifischer Immunität in vielen Patienten, wird der Tumor oft nicht 
kontrolliert. Wahrscheinlich gibt es Mechanismen, die die tumorspezifische Immunität lokal 
unterdrücken.   
Zusammen mit Chemotherapie und operativer Entfernung von Tumoren, ist Radiotherapie eine 
wichtige Therapie für Krebs. Radiotherapie induziert irreversible Schäden in der Erbsubstanz und 
greift daher hauptsächlich schnell proliferierende Zellen an. Obwohl Radiotherapie lange als 
immunsuppressiv galt, gibt es nun immer mehr Hinweise dafür, dass Radiotherapie die 
tumorspezifische Immunität unterstützt und dass die Aktivierung des Immunsystems ein integraler 
Bestandteil dieser Therapieform ist. 
Im ersten Teil dieser Arbeit zeigen wir, dass das Komplement System vorübergehend im 
bestrahlten Gewebe aktiviert wurde. Das führte zur lokalen Produktion der Anaphylatoxine C3a 
und C5a. Es zeigte sich, dass Anaphylatoxine für die radiotherapie-induzierte Reifung von Tumor-
spezifischen dendritischen Zellen, die Funktion von Effektor T-Zellen und die klinische Effizienz 
von Radiotherapie wichtig waren. Unsere Daten zeigen, dass Radiotherapie eine lokale und 
vorübergehende Entzündung auslöst, die die tumorspezifische Immunität unterstützt. Das 
Komplement System ist ein zentraler Bestandteil dieser Entzündungsreaktion. Eine Hemmung der 
Entzündungsreaktion mit Dexamethason, einem Kortikosteroid, welches im Zusammenhang mit 
Radiotherapie oft Patienten verabreicht wird, führte in einem präklinischen Modell zum Rückgang 
der therapeutischen Effizienz der Radiotherapie. Daraus schliessen wir, dass die durch 
Radiotherapie ausgelöste akute Entzündung wesentlich zur therapeutischen Effizienz beiträgt. 
Im zweiten Teil der Arbeit wird der Einfluss von Radiotherapie auf die Struktur und Funktion von 
Tumor-assoziierten Lymphgefässen untersucht. Wir stellten fest, dass die Struktur durch 
Radiotherapie nicht beeinflusst wurde, jedoch die Lymphdrainage verstärkt wurde. 
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Introduction 
 
1. The immune system 
 
1.1 Lymphoid organs 
 
The immune system is composed of organs and vessels that control the production and maturation 
of immune cells. Primary lymphoid organs (PLOs) including bone marrow and thymus are the 
main niches for hematopoietic stem cells (HSCs) and are responsible for the generation of 
leukocytes from progenitor cells. Secondary or peripheral lymphoid organs (SLOs) include spleen, 
regional lymph nodes (LNs), Peyer’s patches, tonsils and mucosa-associated lymphoid tissues 
(MALT). Here mature lymphocytes are maintained and immune responses are initiated (Randall et 
al., 2008). During embryogenesis, multi-lineage HSCs arise from specialized vascular endothelial 
cells in the extraembryonic yolk sac (approx. mouse embryonic day E8.2), in the placenta (day 
E10) and later in the fetal liver (day E11). HSCs home to fetal bone marrow only shortly before 
birth (Hirschi, 2012). The thymus, essential for T cells development, derives from the third 
paryngeal pouch (day E11) and is situated in the upper anterior thorax, just above the heart. It 
consists of numerous lobules, clearly differentiated into an outer cortical region and an inner 
medulla. 
SLOs are the sites where an adaptive immune response is initiated. Immune responses against 
blood-borne antigens are predominantly initiated in the spleen, whereas antigens in tissues reach 
the local lymph nodes with the interstitial tissue fluid during its passage from the periphery to the 
thoracic duct. Peyer’s patches are the most important and highly organized SLOs of the gut and 
MALT are diffusely organized aggregates of lymphocytes that protect the gastrointestinal 
epithelium, together with the tonsils and the respiratory tract.  
Whereas PLOs and SLOs develop in the embryo, tertiairy lymphoid organs (TLOs) can be formed 
at any time after birth under conditions of chronic inflammation including autoimmunity and 
transplant rejection, (chronic) infection or cancer (Aloisi and Pujol-Borrell, 2006). TLOs basic 
structure is very similar to SLOs (Kratz et al., 1996). The presence of TLOs in autoimmunity and 
transplant rejection correlates with more severe clinical disease, whereas TLOs seem the have a 
beneficial role in the context of infections and cancer (Aloisi and Pujol-Borrell, 2006). 
 
1.2 General aspects of the immune system 
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Traditionally, immunologists have studied the innate and adaptive components of immune defense 
as two isolated subsystems. Today, these two components are appreciated to act synergistically in 
protecting the host. 
The innate defense comprises a plethora of mechanisms ranging from non-specific barrier function 
of epithelia to the highly selective recognition of pathogens by germline-encoded receptors. Innate 
responses are usually initiated by disturbances of homeostasis including pathogens and tissue 
damage. Granulocytes, monocytes, macrophages, dendritic cells, natural killer (NK) and innate 
lymphoid cells (ILCs) make up the cellular part of the innate immune system and its most 
important feature is the ability to respond immediately (Janeway and Medzhitov, 2002). 
In contrast, the adaptive immune response is mediated by B and T lymphocytes that recognize 
unique antigens by their B cell receptor (BCR) and T cell receptor (TCR), respectively. Because 
the frequency of lymphocytes with a particular specificity is low, a biologically meaningful 
response can only take place after the relevant lymphocytes have been activated and sufficiently 
expanded, which usually takes at least a week. The generation of antigen-specific memory is a 
unique feature of adaptive immunity. 
Today this strict distinction between innate and adaptive immunity has become blurred. For 
example, NK cells show traits that were considered typical for adaptive immunity, such as 
longevity and recall responses (Sun et al., 2014). In addition, γδT cells, which are classified as 
innate cells because they recognize nonclassical major histocompatibility complex (MHC) class I 
molecules and unprocessed proteins, do require recombination-acivating gene (RAG)-mediated 
recombination, possess restricted TCR repertoires and can develop memory responses (Sheridan et 
al., 2013). Also innate cells that do not require RAG recombination can mount protective recall 
responses against reinfection, like monocytes (Kleinnijenhuis et al., 2012). The recently discovered 
and characterized ILC1, ILC2 and ILC3 show functional similarities with CD8+ T/TH1, TH2 and 
TH17 cells, respectively. ILCs do not undergo antigen-driven clonal selection and expansion, but 
respond to distinct stimuli. For the moment, they are considered the “blueprint” for the adaptive 
arm (Eberl et al., 2015), but the question whether these cells have adaptive characteristic remains 
open. The emerging concept that innate responses control and in fact are a prerequisite for adaptive 
immunity was introduced by Janeway in 1989 (Janeway, 1989). Many components have been 
identified as bridging factors between innate and adaptive immunity, directing the field toward an 
idea of full collaboration between innate and adaptive components (Paul, 2011). Dendritic cells 
(DCs) are crucial cells linking adaptive and innate immunity and were first discovered by Steinman 
(Steinman and Cohn, 1973). Dendritic cells develop in the bone marrow and reside as immature 
DCs in tissues. Upon disturbance, maturation ensues, which results in phenotypic and functional 
changes enablich the mature DC to initiate T cell responses (Banchereau and Steinman, 1998).  
 
1.3 Innate immunity 
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The innate immune system has evolved to recognize many different molecular patterns common to 
pathogens as well as a number of other indicators of cell stress or death. The innate immune system 
is composed of cellular components that derive from the bone marrow or are maintained by self-
renewal in epithelia, where they form the first line of defense against environmental assaults. 
Moreover, a variety of non-cellular components is part of innate defense, ranging from the barrier 
function of the stratum corneum or the enzymes secreted in the sweat and saliva to complex 
systems like anti-microbial peptides (Ganz, 2003), the coagulation cascade and the complement 
system. These non-cellular components act as a physical blockade and can directly destroy 
pathogens or send an alarm to other immune cells.  
Innate cells recognize pathogen-associated molecular patterns (PAMPs) (Janeway and Medzhitov, 
2002) as well as endogenous damages-associated molecular patterns (DAMPs) by pattern-
recognition receptors (PRR), which leads to the production of inflammatory mediators and innate 
host defense. In addition, engagement of PRRs expressed on antigen-presenting cells (APCs), in 
particular DCs, is a strong maturation stimulus and enables the initiation of adaptive immune 
response. Several PRRs have been characterized including Toll-like receptors (TLRs), C-type 
lectin receptors (CLRs) and nucleotide-binding oligomerization domain (Nod)-leucine-rich 
repeated-containing receptors (NLRs) (Kawai and Akira, 2010). Different PRRs display a PRR-
specific subcellular distribution (Barton and Kagan, 2009), which guarantees sensing of most 
PAMPs (Medzhitov, 2008). In general, the combination of enganged PRRs determines the quality 
of the following response such that the resulting, integrated immune response is optimally tuned to 
deal with a particular disturbance (Heredia et al., 2013; Monticelli et al., 2011). 
 
1.4 Adaptive immunity 
 
1.4.1 Lymphocyte development  
 
The main cellular effectors of adaptive immune reactions are B and T lymphocytes. Studies on 
chicken offered a clear view of separate thymus-dependent (T cells) and bursa-dependent (B cells) 
lineageas of lymphocytes that mediate respectively cellular and humoral response (Cooper et al., 
1965). Lymphocyte development starts in the bone marrow (before birth in the fetal liver) from 
common precursors that commit to B or T cells expressing antigen-specific BCR and TCR, 
respectively. The antigen specificity of each lymphocyte is determined by the assembly of V 
(variable), D (diversity) and J (joining) gene segments to generate rearranged V genes encoding the 
antigen-receptor variable (V) region. This recombination is mediated by RAG1 and RAG2 (Oltz 
and Osipovich, 2007). The complete antigen receptor requires the rearrangement of two different 
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genetic loci in order to produce the heavy (H) and the light (L) chain of the BCR or the α and β 
chains (or γ and δ) of the TCR. If this rearrangement is successful, the cell proceeds to the next 
stage of development. The development of both B and T cells depends on stroma cells and it 
strictly regulated (Egawa et al., 2001; Janeway, 2001; van Ewijk et al., 1994). Mature lymphocytes 
circulate through the blood thereby passing through secondary lymphoid organs where they can be 
exposed to antigens (Figure 1).  
Figure 1. Lymphocytes development and activation. Common myeloid and lymphoid progenitors reside in 
the bone marrow (CMP, CLP). The generation of T cells happens with the migration of progenitors to the 
thymus where they undergo maturation through different stages till the formation of CD4 and CD8 T cells. B 
cells develop in the bone marrow and immature B cell can finish their development in the spleen, where they 
progress to generate marginal zone B cells (MZ B cells), follicular B cells and B1 cells. Mature lymphocytes 
circulate through SLOs where they encounter antigens directly or on APCs and interact each other 
(immunological synapses). (Adapted from (Olsen Saraiva Camara et al., 2012)). 
 
1.4.2 B cells  
 
B lymphocyte development depends on the nonlymphoid stroma cells in the bone marrow, which 
interact with the developing B cells through cell-adhesion molecules and production of growth and 
differentiation factors such as stem cell factor (SCF) and IL-7. Commitment to the B cell lineage is 
controlled by several transcription factors such as PU.1, IKAROS, E2A, IRF8 and PAX5 (Fuxa 
and Skok, 2007). The different developmental stages are defined along the functional 
rearrangement of the immunoglobulin gene segments. Heavy chains are assembled from 4 
segments (VH, D, JH and CH); light chains are assembled from 3 segments (VL, JL and CL). In 
humans, there are 9 different heavy chains types (IgM, IgD, IgG1-4, IgA1 and IgA2, and IgE) and 
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2 light chain types (κ and λ). In mice, there are 6 types of heavy chains (IgG1, IgG2a, IgG2b, IgG3, 
IgA and IgM) and 2 light chain types 2 light chain types (κ and λ). 
The development of B cells (Figure 2) starts with pro-B cells (progenitor cells with limited self-
renewal capacity) that rearrange the heavy chain (DH to JH early and VH to DJH late pro-B cells). 
Productive VDJH joining leads to the expression of the rearranged IgM heavy chain and the 
formation of pre-B cells. At this stage the IgM heavy chain pairs with surrogate light chains 
resulting in expression of the pre-B-cell receptor (pre-BCR) on the surface (large pre-B cells). 
Subsequent to signaling through this receptor, light-chain rearrangement begins forming a 
complete IgM molecule. At this stage immature B cells undergo a selection process that happens in 
the bone marrow and subsequently in the SLOs for the elimination of self-reacting cells. Only 
naïve B cells which complete this process can leave the bone marrow (Janeway, 2001; LeBien and 
Tedder, 2008). 
 
 
Figure 2. B-cell development. In the bone marrow, pro-B cells rearrange the immunoglobulin locus 
resulting in the generation of the pre-B-cell receptor (pre-BCR). Signaling through this receptor leads to 
expansion of the precursor, generation of the mature BCR (rearranged heavy- and light-chain genes). These 
cells are called immature B cells and at thi point they undergo a selection process to avoid self-reacting cells. 
Only cells completing this checkpoint leave the bone marrow as immature B cells, capable of recognizing 
antigens. They can eventually mature into mature follicular B cells (or marginal-zone B cells). Following an 
immune response, antigen-specific B cells develop into either plasma (antibody-secreting) cells or memory B 
cells (Cambier et al., 2007).  
 
B cells reside in the lymphoid follicles of the spleen or the LN where they encounter and respond 
to antigens, proliferate and differentiate into plasma cells. In this activated form, B cells secrete a 
free form of the BCR receptors (antibodies or immunoglobulin (Ig)) whith identical binding sites as 
the ones on the plasma membrane. T-dependent antigens require T cell help for maximal antibodies 
production. When B cells present an antigen on MHC class II in the presence of costimulatory 
molecules, T cells produce cytokines that lead to immunoglobulin class switching in B cells. 
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During this process, the heavy chain is changed and the variable region of the heavy chain stays the 
same. In this way, antibody retains affinity for the same antigens, but can interact with different 
effector molecules (Gauchat et al., 1990). Immature B cells can recognize T-cell independent 
antigens such as lipopolysaccharides, eliciting potent response in the absence of MHC class II-
restricted T cell-help (Coutinho and Moller, 1975). B cells which do not became plasma cells enter 
the germinal centers (GC), sites within SLOs where mature B cells undergo clonal expansion, 
differentiation and somatic hypermutation of VH genes and selection for increased affinity of a 
BCR for its unique epitope (Muramatsu et al., 2000). GCs containing rapidly dividing cells are the 
main site for high-affinity antibody-secreting plasma cell and memory B cell generation (Jacob et 
al., 1991). The disruption of this equilibrium regulating activating and inhibitory signals of normal 
B cell activation and longevity can predispose to pathogenic autoantibody production and 
autoimmunity (Vinuesa et al., 2009). Besides antibody-dependent defense, B-1 B cells provide an 
innate protection against bacterial infection (Haas et al., 2005) and mariginal zone (MZ) B cells 
constitute the first line of defense against blood-borne encapsulated bacteria (Pillai et al., 2005). 
 
1.4.3 T cells  
 
T cells develop in the thymus from common lymphoid progenitors cells (CLPs) (Hedrick, 2008) 
(Figure 3). CD4-CD8- (double negative) CLPs are attracted to the corticomedullary junction by 
CCL21 and other chemokines. CLPs interact with the adhesion molecules on thymic epithelium, 
rapidly expand and induce expression of fundamental genes for TCR assembly resulting in 
commitment to the T cell lineage (Gordon and Manley, 2011). 
 
 
Figure 3. Schematic representation of thymic T cell development. The different stages of T cell 
maturation from the CLPs to the single positive T cells (SP), happen in different areas of the thymus. The 
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expression of CD4 or CD8 separates the double positive (DP) and SP cells from the double negaive CD4-
CD8- cells (DN) present in the initial stages	(Germain, 2002).  
 
During their development, thymocytes rearrange the T cells receptor at the γ, δ, and β loci 
(MacDonald et al., 2001). In a spatially ordered process, one V, one D and one J segment are 
randomly spliced together by RAG1 and RAG2. The structures that result from the recombination 
dictate the amino acid sequence and the binding specificity of the TCR	(Oltz and Osipovich, 2007). 
The successful recombination of Tcrd and Tcrg concomitant with other signals, promotes γδ T cell 
specification (Lauritsen et al., 2009). αβ T cells continue their development and if a stable complex 
is formed by CD3, TCRβ and invariant pre-TCRα, they start to travel towards the medulla and to 
express CD4 and CD8 becoming double positive cells (DP) (von Boehmer, 2005). DP thymocytes 
that interact with intermidiate avidity for self-peptide-MHC complexes presented by cortical 
thymic epithelial cells (cTECs) undergo positive selection, the surviving DP express self-MHC-
restricted TCRs (Klein et al., 2009; Kyewski and Klein, 2006) (Figure 4).  
 
 
Figure 4. Positive and negative selection. T cell undergo positive selection in the thymic cortex and it is 
mediated by cTEC. T cells that survive the process migrate toward the medulla in which they are negatively 
selected by mTEC and dendritic cells (Klein et al., 2009).  
 
The amount of CD5 on T cells is thought to reflect the signaling intensity of the positively selecting 
TCR-MHC interaction (Azzam et al., 1998), and the observation that CD5low T cell clones are 
favored in the process of positive selection suggests a selection against TCRs with a too high 
affinity, maybe to avoid autoimmunity (Nitta et al., 2010). Those T cells that are not positively 
selected, which are the majority, are eliminated by apoptosis in the thymic cortex	(Surh and Sprent, 
1994). 
Positively selected DP thymocytes commit to the single positive CD4 or CD8 lineage (SP CD4 or 
SP CD8). SP cells migrate into the medulla where they undergo negative selection or clonal 
deletion (central tolerance), a process by which TCRs with high affinity for self-antigens are 
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eliminated, thus reducing the autoreactive T cell pool (Figure 4). Medullary thymic epithelial cells 
(mTECs) express all self proteins, including tissue-restricted antigens (TRAs) (Derbinski et al., 
2001) and present them to T cells, which usually results in death of the T cell. This so-called 
ectopic expression of self proteins depends on the transcription factor Aire and Aire-deficient mice 
develop spontaneous generalized autoimmunity (Anderson et al., 2002), which underscores the 
importance of negative selection or central tolerance induction for prevention of autoimmunity. 
Proteins expressed by mTECs are directly presented to T cells (Hinterberger et al., 2010; Klein et 
al., 1998; Oukka et al., 1996) or can be handed over to and presented by neighbouring APCs 
(Koble and Kyewski, 2009). Migratory DCs contribute to clonal deletion because they transport 
peripheral antigens to the thymic medulla	(Baba et al., 2009). 
Besides cell death, high-affinity interactions between the TCR and self-peptide-MHC in the thymic 
medulla can result in development of invariant natural killer (iNKT), CD4+ regulatory T cells (Treg 
cells) and the precursor of intrepithelial lymphocytes (IELs). This process is called clonal diversion 
(Cowan et al., 2013; Stritesky and Hogquist, 2012). The specific mechanism how mTECs and DCs 
manage to elicit clonal diversion is not yet clear, but it seems to be a complex interplay between 
these two cell types and transcription factors present in the CD4+ T cells (Lei et al., 2011). 
Thymocytes with high-affinity TCR can avoid deletion or diversion via secondary gene 
rearrangement of the TCRα locus, thereby changing the specificity of the TCR in a process known 
as receptor editing (Holman et al., 2003).  
Thus, positive and negative selection favors development of T cells with an adequate affinity to 
self-MHC and little reactivity to self proteins (Klein et al., 2014). Thymic selecton is not 100% 
accurate and some autoreactive T cells sneak through. Such T cells pose a risk for autoimmunity 
but at the same time seem instrumental for immunity against cancer. Peripheral tolerance usually 
prevents activation os such T cells (Yan and Mamula, 2002).  
Less than 5% of all thymocytes leave the thymus to differentiate into mature T cells (Starr et al., 
2003) that form the long-lived pool of naïve T cells that recirculate within the SLOs. The low self-
reactivity that T cells retain after thymic selection is essential for naïve cell survival and enhances 
the TCR sensitivity for foreign antigens (Klein et al., 2014; Krogsgaard et al., 2007). Recognition 
of an antigen leads to massive expansion of naïve T cells that goes on for several days, and to the 
acquisition of a protective effector function. Most effector T cells die within the next weeks, but a 
small fraction of T cells survive almost indefinitely as memory T cells (Farber et al., 2014; Sallusto 
and Lanzavecchia, 2001). 
TCRγδ T cells develop in the thymus as well and populate intraepithelial compartments (IEL) of 
the skin, intestine and genitourinary tract (Asarnow et al., 1988; Sato et al., 1993). They recognize 
either pathogen-derived antigens or self molecules that reflect a disregulated status (Janeway et al., 
1988). The recognition of these antigens is independent of MHC presentation, but more dependent 
on conformational shape of intact protein or non-protein compounds (Girardi and Hayday, 2005). 
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This propterties render γδ T cells able to participate in the early stages of an immune response in a 
process named lymphoid stress-surveillance (Hayday, 2009). 
NKT cells develop in the thymus and are CD1d-restricted T cells that express an invariant TCRα 
combined with a limited TCR β-chain repertoire (Godfrey et al., 2004). The resulting TCR 
recognizes glycolipid antigens presented by CD1d (Bendelac et al., 2001). NKT cells play a role in 
many different diseases and can both promote and suppress the immune response	 (Godfrey et al., 
2010). 
 
 
2. The immune response 
 
2.1 Antigen presentation and antigen-presenting cells 
 
MHC molecules are highly polymorphic surface molecules encoded by a large gene family that 
control major parts of immune responses in vertebrates. The MHC gene family consists of class I, 
II and III molecules. MHC class I molecules consist of a variable heavy chain that is non-
covalently associated with a light conserved β2-microglobilin molecule, whereas MHC class II 
molecules consist of two variable chains (α and β chain) (Figure 5). MHC class III molecules 
comprise proteins that are not involved in antigen presentation such as complement components, 
heat shock proteins and TNFα (Janeway, 2001). In addition to the highly polymorphic “classical” 
MHC class I and class II genes, there are other genes linked to the MHC class I region encoding for 
MHC class 1B molecules. These molecules have different functions, for example, CD1 that is 
expressed on DCs, thymocytes and monocytes is structurally related to MHC class I and it presents 
glycolipids in particular to NKT cells (Barral and Brenner, 2007). MHC class I and II molecules 
binds protein fragments and the peptide/MHC complex can be recognized by T cells through their 
TCR. MHC class I is expressed by all nucleated cells, whereas the expression of MHC class II is 
limited to dendritic cells, macrophages and B cells under steady state, although expression can be 
induced on many cell types under particular conditions such as inflammation. MHC class II 
expression is tightly controlled by the regulator MHC class II transactivator (CIITA) (Reith et al., 
2005). 
MHC class I molecules present antigens derived from proteasomal degradation of proteins in the 
nucleus or in the cytosol. In 1996, Yewdell and colleagues suggested that many presented peptides 
derive from defective ribosomal products (DRiPs), which are prematurely terminated polypeptides 
and misfolded proteins that are rapidly degraded and efficiently access the class I pathway. 
Aminopeptidases trim and destroy most of the peptides and only 0.1% of peptides are translocated 
into the ER by the transporter associated with antigen presentation (TAP). Peptides of 8-9 amino 
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acids are loaded on MHC class I molecules by the peptide-loading complex (PLC). Peptide-MHC 
class I complex is finally released by the PLC and translocated to the cell membrane (Lev et al., 
2008; York et al., 2002) (Figure 5A). 
 
  
Figure 5. The MHC class I and II presentation pathway. A) MHC class I molecules are situated in the 
endoplasmic reticulum (ER) and can be loaded with peptides coming from proteins degraded by 
proteasomes. The transported associated with antigen presentation (TAP) translocateds peptides into the ER 
lumen and when MHC class I are in complex with the antigens, they are transported to the plasma membrane 
via Golgi and present the antigen to the CD8+ T cells. B) MHC class II molecules are assembled in the ER 
and then transported via Golgi to the MHC class II compartment (MIIC). The invariant chain (Ii) is degraded 
in these vesicles along with endocytosed proteins. MHC class II molecules left with the MHC class II 
associated Ii peptide (CLIP) can be loaded only with high affinity peptides with the help of the chaperon H2-
DM. At the end of the process they are transported to the plasma membrane and present the antigen to CD4+ 
T cells (adapted from (Neefjes et al., 2011)). 
 
Specific subsets of APCs can also present exogenous antigens on MHC class I in a process called 
cross-presentation (Kurts et al., 2010). It has been recently shown that authophagy (a catabolic 
process by which the cell eliminates unnecessary or dysfunctional components by lysosomal 
degradation) can result in loading of peptides derived from endogenous proteins on MHC class II 
(Munz, 2009). 
MHC class II subunits are associated to the invariant chain and then transported to late endosomes, 
also called MHC class II compartment (MIIC). In this compartment, the invariant chain is digested 
and a peptide is left in the binding grove of the MHC class II heterodimer. The chaperone H2-DM 
is needed to exchange the peptide in the binding groove with high affinity peptides. MHC class II 
molecules in complex with peptides are then transported to the plasma membrane to present the 
A B 
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peptide to the CD4+ T cells (Neefjes et al., 2011) (Figure 5B). CD8+ T cells interact with MHC 
class I and CD4+ T cells with MHC class II molecules.  
There are many different APCs that can trigger T cells, including B cells, macrophages, endothelial 
cells and DCs, but DCs are the quintessential professional APCs (Steinman and Cohn, 1973). DCs 
were first identified by Steinman and Cohn as cells with dendrites, which gave the cells their name 
(Steinman and Cohn, 1973). DCs originate from bone marrow precursors that seed different tissues 
via the blood and locally differentiate into specialized sentinels. All DCs subsets are equipped with 
different PRRs, including TLRs, on the plasma membrane or in the cytosol. Ligation of TLRs leads 
to DC maturation, which results in the production of soluble factors and endows DCs with the 
capacity to activate naïve T cells during cognate interaction (Akira et al., 2006; Blander and 
Medzhitov, 2006; Sporri and Reis e Sousa, 2005). The efficiency of dendritic cells as antigen 
presenting cells depends on several important charcateristics. Upon maturation antigen processing 
function are increased (Delamarre et al., 2003; West et al., 2004). DCs express high levels of MHC 
class II (Schuler and Steinman, 1985) and have decreased proteolytic capacity compared to that of 
other phagocytes, which results in efficient cross-presentation (Delamarre et al., 2005). Moreover, 
DC phagosomes are characterized by the presence of MHC class I loading ER-resident proteins 
(Guermonprez et al., 2003; Houde et al., 2003). 
DCs can be classified in two main categories: plasmacytoid DCs (pDCs) and conventional DC 
(cDCs) (Turley et al., 2010). The development of pDCs is controlled by the transcription factor E2-
2. pDCs produce type I interferons and IL-12 upon stimulation (Swiecki and Colonna, 2010). 
Conventional DCs can be subdivided in two categories based on their development: cDC1, 
controlled by BATF3 and cDC2 by IRF4 (Guilliams et al., 2014). In general, conventional DCs are 
identified by the surface markers CD11c+ MHCII+, but they can express several other markers 
based on their function. Recently, the chemokine receptor Xcr1 has been identified as a specific 
marker for the BATF3-dependent CD8α+ T cells (Bachem et al., 2012; Dalod et al., 2014). Xcr1+ 
DCs have been identified as the most efficient in presenting antigens on cross-presentation (Joffre 
et al., 2012). However there are some features that could explain the superior cross-presentation 
capacity: Xcr1+ DC maintain a less acidic pH in endosomes and phagosomes, favoring cross-
presentation from early endocytic vesicles (Savina et al., 2009); they are more efficient at 
translocation of Ags to the classical MHC I processing pathway (Segura et al., 2009); and finally 
they express high level of TLR3 which is an enhancer of cross-presentation (Schulz et al., 2005).  
 
2.2 T cell fates: priming, peripheral tolerance and exhaustion 
 
Naïve T cells recirculate continuously between the blood and the SLOs until they encounter their 
antigen. Signaling through the TCR can have different consequences that range from differentiation 
into effector and subsequent memory cells, tolerance induction to exhaustion. The strength of the 
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TCR signal is determined by the number of peptide-MHC complexes and costimulatory molecules 
on the APC (Lanzavecchia and Sallusto, 2002), whereas cytokines modulate the quality of the 
ensuing T cell response. Although other cell types including B cells (Gonzalez et al., 2009), 
macrophages (Backer et al., 2010; Delamarre et al., 2005) and stromal cells, like fibroblastic 
reticular cells (Fletcher et al., 2010; Lee et al., 2007), can present antigen to T cells, activated or 
mature DCs are unchallenged in their capacity to activate naïve T cells (Steinman and 
Nussenzweig, 2002). However, immature DCs are major inducers of peripheral T cell tolerance 
under steady state conditions and therefore crucial to prevention of autoimmunity (Hawiger et al., 
2001; Probst et al., 2003). 
Figure 6. Basic illustration of cross-priming. Dendritic cells (DCs) present the antigen to CD4+ T helper 
(TH) cells through MHC class II molecules and cross-present it to CD8+ cytotoxic T lymphocytes through 
MHC class I molecules. Mature DCs upregulate expression of co-stimulatory molecules, such as CD70, 
CD80 and CD86. TLR ligands further activate DCs and increase their cross-presentation activity. TH cells 
can stimulate CTLs through the production of IL-2, (adapted from (Kurts et al., 2010)).  
 
Infection, inflammation and adjuvants result in production of PAMPs or DAMPs that are sensed by 
DCs via by a vast array of PRR and result in functional and phenotypic changes of DCs, a process 
termed DC maturation (Figure 6). TLRs are responsible for DCs polarization and promotion of 
different type of T cell response, including regulatory T cell response (Kapsenberg, 2003). During 
the interaction between mature DCs and T cells the immunological synapse is formed, which 
contains TCR/peptide-MHC complexes and cosignaling molecules (Friedl et al., 2005). Choudhuri 
and colleagues provided a new model for the immunological synapse: the tumour susceptibility 
gene 101 (TSG101) sorts TCRs for inclusion in microvesicles that subsequently bud at the center 
of the immunological synapse. Vacuolar protein sorting 4 (VPS4) mediates scission of 
microvesicles from the T-cell plasma membrane (Choudhuri et al., 2014), which may explain TCR 
downregulation upon congnate interactions. Productive activation of naïve T cells requires three 
signals (Marchingo et al., 2014). Signal 1 is delivered through the TCR and guarantees antigen-
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specificity of the response. Without concomitant signals 2 and 3, however, signal 1 promotes T cell 
unresponsiveness (anergy, peripheral T cell tolerance). Signal 2 consists of co-stimulatory and co-
inhibitory signals that are integrated by the T cell to define the ultimate type of response. The 
prototype co-stimulatory interaction consists of CD28 on the T cell and CD80/CD86 on the APC. 
CD28 was the first co-stimulatory molecule that was identified and was shown to be crucial to the 
production of the T cell growth factor IL-2 (Linsley et al., 1991). A variety of stimuli can quickly 
upregulate CD80 and CD86, otherwise consitutively present on the DCs, which are early 
costimulatory signals. The complexity of co-stimulation is illustrated by the fact that CD80/CD86 
also interact with a co-inhibitory moldecule on T cells, like CTLA-4. The latter binds CD80/CD86 
with higher affinity than CD28 and it provides a negative feedback loop that down regulates T cell 
response (Carreno et al., 2000; Greene et al., 1996). ICOS is another co-stimulatory molecule 
expressed on CD4+ T cells which depending on the inflammatory environment drives T cell 
polarization (Kopf et al., 2000). CD8+ and CD4+ requires differential co-stimulatory molecules in 
their responses, indicating distinct mechanisms involved in developing effector (Kaech et al., 
2002). Signal 3 is the polarizing signal delivered from the APCs to the T cells, which usually 
consists of cytokines and determines in which type of effector cell  T cells will differentiate (Chen 
and Flies, 2013). For example, IL-12 promotes differentiation of TH1 cell or cytotoxic T 
lymphocytes (CTLs) (Trinchieri, 2003) and type I IFN supports clonal expansion and 
differentiation of naive CD8 T (Curtsinger et al., 2005). 
Naïve CD4 T cells require a minimum of 6 hours (Iezzi et al., 1998) and naïve CD8+ T cells 2-24 
hours (van Stipdonk et al., 2001) of antigenic stimulation to commit to clonal expansion and 
effector differentiation. The signal through the TCR is driving T cells through a hierarchical 
threshold of differentiation determining the strength of the response (Lanzavecchia and Sallusto, 
2002). Activated, proliferating T cells leave the LN and undergo different fates, depending on the 
migratory capacities. T cells expressing CCR7 and L-selectin have access to T cell areas of the LN, 
where they can be further stimulated by the survival-promoting cytokines such as IL-2, IL-7 and 
IL-15. By contrast, T cells with tissue-homing capacity can migrate to inflamed tissues, where they 
complete their differentiation (Roman et al., 2002). After activation and proliferation, the majority 
of T cells die, leaving behind an heterogeneous pool of memory T cells, which can provide life-
long protection. The original model was elaborated by Sallusto and colleagues showing that 
memory T cells circulate in the bloodstream as two distinct subsets: Central memory (TCM) T cells 
that express CCR7, CD62L (L-selectine), can proliferate produce IL-2, and effector memory T 
cells (TEM) that do not express CCR7 or CD62L, are less proliferative and produce IFNγ (Sallusto 
et al., 1999). TCM are predominant in the SLOs and TEM are predominant in the peripheral 
compartments (Masopust et al., 2001). Recently, a third subpopulation of memory T cells was 
identified, the tissue-resident memory T cells (TRM) that permanently reside in tissues and mediate 
local protection (Gebhardt et al., 2009). Differently distributed memory T cells provide a fast and 
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enhanced protection from reencounter of the same antigens (Schenkel et al., 2013; Sheridan et al., 
2013).  
T cells chronically exposed to antigens, for example during chronic viral infection or within tumor 
microenvironments, may adopt an altered phenotype characterized by a reduced proliferative 
capacity and effector function (Wherry, 2011). These T cells have been termed “exhausted” T cells 
because they  do not respond to ongoing stimuli. This phenomenon was first identified in CD8+ T 
cells (Moskophidis et al., 1993), but also CD4+ T cells can develop an exhausted phenotype 
(Oxenius et al., 1998). One well-defined mechanism associated with exhaustion is the upregulation 
of inhibitory molecules like PD-1, CTLA-4 and TIM3 (Fourcade et al., 2012; Wherry, 2011). IL-10 
and TGFβ have been associated with exhaustion too (Tinoco et al., 2009). The final stages of 
exhaustion are the lack of the ability to produce IFN-γ and the elimination of effector cells 
(Moskophidis et al., 1993; Wherry, 2011). T cell exhaustion, besides interfering with effector 
function, can prevent the development of highly functional memory T cells (Shin and Wherry, 
2007). Interestingly, T cell exhaustion might be rescued blocking inhibitory molecules, cytokines 
or through costimulatory signals. For example, it has been shown in a model of chronic infection 
with lymphocytic choriomeningitis virus (LCMV) that an agonist monoclonal antibody specific for 
4-1BB (transmembrane glycoprotein belonging to the TNF expressed on activated T cells) in 
combination with IL-7, can restore the activity of dysfunctional CD8+ T cells (Wang et al., 2012). 
Moreover, blockade of PD-1 was described as promising in rescuing T cells function in chronic 
infection and cancer (Pauken and Wherry, 2015; Sakuishi et al., 2010). These findings are the 
prove of principle that exhausted T cells are not completely terminal. Reverting the exhausted 
phenotype of T cells might be a promising approach for enhancing immunity during chronic 
insults. 
There is ample evidence that immature DCs in the steady state tolerize CD4+ and CD8+ T cells by 
inducing deletion or tolerance (Steinman et al., 2003; Steinman and Nussenzweig, 2002). This 
represent an homeostatic system to take under control the peripheral T cell repertoire of 
autoreactive T cells that escaped thymic deletion, contributing in limiting autoimmunity (Steinman 
and Nussenzweig, 2002). DCs which have not sensed PAMPs and/or DAMPs through TLRs or 
other sensor molecules, do not mature completely. Consequently, instead of breaking the peripheral 
tolerance of T cells, they present MHC/peptide complexes that cause T cells anergy (process 
termed cross-tolerance), because of the lack of costimulatory molecules (Kurts et al., 1997; Probst 
et al., 2005; Steinman et al., 2003). DCs tolerogenicity is not specific to a single subsets and it can 
also be induced and maintained by various anti-inflammatory and immunosuppressive agents, 
including IL-10 (Morelli and Thomson, 2007). Additionaly, co-inhibitory molecules can provide 
negative signals that inhibit T cells response, mediate T cells tolerance, preventing autoimmunity. 
These receptors are programmed cell death 1 (PD-1) and cytotoxic T lymphocyte (CTL)-associated 
antigen 4 (CTLA-4) and their ligands are respectively PD-L1/2 and CD80/CD86. It has been 
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demonstrated that resting, antigen-presenting DCs induce tolerance through the engagement of PD-
1 and CTLA-4 (Probst et al., 2003; Probst et al., 2005). In the absence of the signal 2, signal 1 from 
APCs induces in T cells a state of long-term hyporesponsiveness termed “anergy”. Tregs have been 
postulated to promote an hypoxic environment able to regulate T cells by anergy (Sitkovsky, 
2009). Moreover, lymph nodes stromal cells, like fibroblastic reticular cells (FRCs), follicular DCs 
and lymphatic endothelial cells (LECs), can also present antigens and induce tolerance (Cohen et 
al., 2010).  
 
2.3 The complement system: a bridge between innate and adaptive immune response 
 
Complement is an ancient defense mechanism and is considered a bridge between innate and 
adaptive immunity (Zhu et al., 2005). The complement system consists of more than 30 soluble and 
surface proteins and can be activated through 3 different pathways: the classical, lectin and 
alternative pathway. The classical pathway starts when C1q binds to an immune complex (antigen-
antibody), subsequently activates C1s and C1r and ultimately results in the cleaveage of C4 and 
C2. The lectin pathway is initiated when mannose-binding lectin (MBL) binds carbohydrate motifs 
that are found on bacteria and subsequently activates the MBL-associated serine proteases 
(MASPs), leading to cleavage again of C4 and C2. In both the lectin and classical pathways the 
cleavage products of C4 and C2 form C3 convertase, which cleaves the central protein of the 
complement system (C3) into C3b, C3c and C3a. C3b associates with C4bC2a complex to form C5 
convertase of the classical and lectin pathway. The alternative pathway is activated when C3 
undergoes spontaneous hydrolysis in the presence of Factor B and D and the subsequent formation 
of the C5 convertase of the alternative cascade (C3bBbC3b). The final step is the formation of the 
membrane attack complex (MAC) (Figure 6), which is involved in lysis of target cells.  
The anaphylatoxins C3a and C5a are potent pro-inflammatory mediators that act as opsonins by 
binding the surface of target cells that need to be eliminated by phagocytes (Walport, 2001a; 
Walport, 2001b). Because of its destructive potential, complement activation is tightly regulated by 
soluble (factor H) and membrane-bound inhibitors (CD46, CD55 and CD59) that interfere with the 
activation of convertases or the formation of the MAC (Liszewski et al., 1996). 
Complement receptors are expressed by many cell types, including leukocytes. It has been 
demonstrated that upon infection the priming of CD4+ and CD8+ T cells is reduced in the absence 
of C3 (Kopf et al., 2002). Morever, anaphylatoxins are crucial to T cell costimulation because they 
enhance costimulatory signals on DCs (Strainic et al., 2013). In fact, C5a receptor signal 
transduction in T cell is important to allow optimal T-cell expansion, as well as to maintain 
viability (Lalli et al., 2008). Recent studies demonstrated that anaphylatoxins are crucial mediators 
during the cognate interaction between DCs and naïve CD4+ T cells without which T cells develop 
into Tregs instead of effector cells (Le Friec et al., 2013; Strainic et al., 2013). Anaphylatoxins 
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(C3a and C5a) are products of the cleavage of complement factor 3 (C3) and complement factor 5 
(C5) and can be generated by both DCs and T cells (Strainic et al., 2013). 
 
 
 
Figure 6. The 3 pathways of the complement system. Complement can be activated through the classical, 
alternative and lectin pathway. The initiation phase is mediated but different factors specific for each 
pathway. The 3 pathways culminate with the production of C3 and C5 convertases that leas to the production 
of factors involved in inflammation (anaphiylatoxins: C3a, C5a, C4a); lysis of target cells (MAC) and 
oposonization (C3b, C3bi, C4b), (Dunkelberger and Song, 2010). 
 
The complement system contains some of the most powerful proinflammatory molecules. Acute 
inflammation is a host reponse to infection, injury or disturbance that lasts until the insult is 
cleared. When acute inflammation becomes dysregulated, excessive or chronic it can lead to 
several pathologies. There is a variety of inflammatory disorders like arthritis, autoimmune 
diseases, asthma, ischemia/reperfusion injuries and cancer. 
Complement plays an important and mostly beneficial role in acute inflammation as it contributes 
to resolution of the disturbance (Guo and Ward, 2005; Markiewski and Lambris, 2007). In contrast, 
complement aggravates the detrimental consequences of chronic inflammation and the use of 
complement inhibitors in chronic inflammatory diseases is currently being tested in preclinical 
models and clinical trials (Ricklin and Lambris, 2013). 
Cancer is linked with chronic inflammation but a role of complement in cancer initiation or 
progression is controversial. On the one hand, there is evidence for the presence of activated 
complement in cancer patients (McConnell et al., 1978) and for a tumor-promoting role of 
complement via immune suppression (Markiewski et al., 2008). On the other hand, tumor cells 
express complement regulators in order to escape the control mediate by complement (Li et al., 
2007) and production of anaphylatoxins at low levels has been related with reduced tumor growth 
and better immune respose (Gunn et al., 2012). One possible hypothesis is that complement, 
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activated in a chronic fashion, might create a selective pressure in the tumor microenvironment 
causing tumor growth (Pio et al., 2013); instead acute activation of the complement pathway may 
lead to improved immune reponse and tumor control (Surace et al., 2015). 
 
3. Tumor Immunology 
 
3.1 Immunity against cancer 
 
It is accepted now that the immune system detects and can control cancer. Paul Ehrlich was the 
first in the early 1900s to propose involvement of the immune system in tumor control. Based on 
observations in animal models, Burnet and Thomas as well as Old proposed the theory of “immune 
surveillance of cancer” in the 1950s, speculating that lymphocytes detect tumor antigens on 
transformed cells to destroy them (Burnet, 1957; Old and Boyse, 1964; Thomas, 1982). However, 
Stutman’s observations in 1975 that athymic nude mice did not have increased susceptibility to 
chemically induced tumors almost destroyed the field of tumor immunology (Stutman, 1974). 
Today we know that nude mice have residual numbers of T cells as well as high numbers of NK 
and other immune cells (Dunn et al., 2004). This notion together with the discovery of tumor 
necrosis factor (Carswell et al., 1975) and the identification of the genes encoding tumor antigens 
recognized by T cells (van der Bruggen et al., 1991), revived the tumor immunology and the 
involvement of the immune system in cancer is now a well established concept (Gajewski et al., 
2013). The basic idea of tumor immunology is that cancer cells express antigens that discriminate 
them from their non-transformed counterparts (Cheever et al., 2009; Old, 1981). Besides protecting 
the host against cancer, it is quite clear that the immune system also shapes the immunogenicity of 
the tumor in a dynamic process called cancer immunoediting (Dunn et al., 2004; DuPage et al., 
2012; Schreiber et al., 2011; Vesely et al., 2011). Cancer immunoediting involves 3 phases termed 
elimination, equilibrium and escape and is therefore often referred to as the 3E-concept (Figure 7). 
The elimination phase depends on danger signals such as type I IFNs, damage-associated 
molecular patterns (DAMPs), stress ligand (like RAE-1 and H60) for the stimulation of innate and 
adaptive immune cells (Sims GP, Ann Rev Imm 2010). Studies in knock out mice showed that 
IFN-γ, perforin, Fas/FasL, TRAIL, and NKG2D are fundamental in the elimination phase. Recent 
studies showed that type I IFNs are required for initiation in the initial phases because they enhance 
cross-presentation by CD8α+CD103+ DCs (Fuertes et al., 2011). One problem with studying the 
elimination phase is to distinguish between tumors that were eliminated and tumors that were never 
there. Good models for elimination are still missing, but all evidence points towards a crucial role 
for CD8+ T cells and NK cells (Biroccio et al., 2013; Gasser et al., 2005). 
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If tumor cells survive the elimination phase, the equilibrium phase may occur. The immune system 
controls the outgrowth of the tumor, maintaining tumor cells in a state of dormancy and in parallel 
shaping the immunogenicity. Existence of the equilibrium phase has been assumed for considerable 
time but was difficult to prove until a seminal study showed that interfering with adaptive 
immunity resulted in outgrowth of stable masses of transformed cells in mice (Koebel et al., 2007). 
It should be noted that it is unclear which proportion of cancers are fully eliminated or kept in 
equilibrium by the immune system, because such events are clinically unnoticed. 
In the escape phase, tumor cells have acquired the ability to circumvent the immune control by 
different mechanisms including selection of tumor cells that lack expression of rejection antigens 
of MHC, inefficient antigen presentation to tumor-specific T cells and the promotion of an 
immunosuppressive environment (Schreiber et al., 2011).  
CD8+ T cells are key players in each single phase of the cancer immunoediting process. High 
numbers of CD8+ tumor infiltrating lymphocytes (TIL) correlates with increased survival in 
patients with solid tumors (Fridman et al., 2012). Tumors arising in Rag2-/- mice (lacking T and B 
cells) are more immunogenic than those derived from an immunocompetent host, which explained 
by selective outgrowth of escaped tumors in immunocompetent mice (DuPage et al., 2012; 
Schreiber et al., 2011). Experiments comparing Rag2-/- and Rag2-/- x γc-/- (lacking also NK cells), 
demonstrated that innate cells present in Rag2-/-, but not in Rag2-/- x γc-/- mice, also may contribute 
to shaping immunogenicity of a tumor (O'Sullivan et al., 2012). 
 
 
Figure 7. The cancer immunoediting concept. After cellular transformation has occurred and intrinsic 
tumor suppression mechanism have failed to control tumor development; an additional extrinsic mechanism 
takes place and this is called immunoediting. It consists of 3 phases: elimination, equilibrium and escape. 
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Transformed cells can be recognized by the immune system and destroyed in a phase called elimination. If a 
rare cell variant survive this process, it may enter an equilibrium phase in which different immune cell types 
and molecules collaborate to maintain the tumor in a state of dormancy. In this phase the editing process 
happens. However, due to the constant immune selective pressure, tumor cell variants that are no longer 
recognized or that create a suppressive environment can emerge leading to the outgrowth of the tumor. These 
tumor cells enter the escape phase in which their development is no longer under the control of the immune 
system. At this stage the tumor became clinically apparent (Schreiber et al., 2011). 
 
3.2 The major stumble stones for immunity against cancer 
 
The major problems for immune control of cancer are central tolerance to tumor-associated 
antigens resulting in absence of high-affinity tumor-specific T cells, insufficient innate stimulation 
resulting in defective T cell activation and cancer-associated immunosuppression resulting in 
blunted protective immunity (Baitsch et al., 2012). 
The recognition of tumor-associated antigen (TAA) presented by MHC on tumor cells or APCs is a 
fundamental step for T cell-mediated tumor control. TAA can be divided in neoantigens, which 
originate from viruses or mutations, and self-antigens that are overexpressed host proteins (Coulie 
et al., 2014). It was thought for a long time that central tolerance was limited to ubiquitously 
expressed proteins, however, Kyewski and colleagues showed that all proteins including tissue-
specific proteins are expressed by medullary thymic epithelial cells and induce central tolerance 
(Kyewski and Klein, 2006; Kyewski et al., 1984). Similar data were shown for human TAA (Gotter 
et al., 2004). This has consequences for the quality of most tumor-specific T cells because the 
peripheral T cell repertoire will be purged of self-reactive T cells with a high-affinity TCR 
(Redmond and Sherman, 2005). 
Although spontaneous tumor-specific responses are observed in some cancer patients, the effector 
function of such T cells often is compromized. Insufficient innate stimuli lead to defective DC 
maturation thus precluding proper T cell priming. Especially tumor-associated DCs seem 
tolerogenic as they express low amounts of MHC and co-stimulatory molecules and produce the 
immunosuppressive cytokine IL-10 (Gabrilovich, 2004). Growing tumors progressively contain 
more immunosuppressive factors and less pro-inflammatory signals that impair DC maturation and 
development or maintenance of protective immunity (Bell et al., 1999; Troy et al., 1998; Zou et al., 
2001), which also seems to be the case for tumor-draining lymph nodes (Fujita et al., 2009). Many 
tumors upregulate vascular endothelial factor C (VEGF-C), which increases lymphangiogenesis 
causing an increased delivery of TAAs (Pepper, 2001). The prolonged exposure to TAAs in the 
absence of sufficient innate stimuli may cause exhaustion of T cells (Bucks et al., 2009; Hansen et 
al., 2007). Moreover, lymphatic endothelial cells (LECs) can take up and present TAAs to CD8+ T 
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cells. Since LECs lack costimulatory molecules and express PD-L1, this causes tolerization of T 
cells (Lund et al., 2012).  
Even if tumor-specific effector T cells are produced and manage to infiltrate the tumor, the 
immunosuppressive microenvironment seriously hampers protective immunity and tumors have 
several mechanism at their disposal to evade immune attack. Tumor cells escape recognition of 
CTLs by downregulating MHC class I molecules (Fonsatti et al., 2003; Meissner et al., 2005) and 
by expressing different or less immunogenic antigens (Khong and Restifo, 2002). Besides avoiding 
the recognition by T cells, the tumor microenvironment impairs immune infiltration by altering the 
expression of adhesion molecules such as E-Selectin and P-Selectin (Weishaupt et al., 2007). High 
levels of TGF-β have been associated with unfavorable prognosis in different malignancies (Curiel 
et al., 2004; Drake et al., 2006). TGF-β controls T cell homeostasis by inhibiting activation, 
proliferation and differentiation (Kehrl et al., 1986). IL-10, together with other factors, blocks DC 
maturation, lymphocyte function and promotes the recruitment of Tregs and myeloid-derived 
suppressor cells (MDSCs) (Bergmann et al., 2007; Serafini et al., 2006). Tregs and MDSCs impair T 
cell function through direct contact or by secretion of immuomodulatory molecules. MDSCs 
produce reactive oxygen species (ROS), which impair the TCR interaction with the MHC/peptide 
complex and induce T cell tolerance locally in the tumor (Nagaraj et al., 2007). High numbers of 
Tregs in the tumor correlates with reduced survival in most human cancers analyzed (Curiel et al., 
2004; Kono et al., 2006) and selective depletion of Tregs results in CD8+ T cell-mediated tumor 
rejection (Carretero et al., 2015; Turk et al., 2004). Moreover, inhibitory coreceptors, such as 
CTLA-4 and PD-1 are crucial to peripheral T cell unresponsiveness. Mice deficient for CTLA-4 or 
PD-1 spontaneously develop autoimmunity (Nishimura et al., 1999; Tivol et al., 1996; Waterhouse 
et al., 1995) suggesting that these molecules are crucial to maintenance if self-tolerance. Allison 
and colleagues were the first to demonstrate that blockade of CTLA-4 enhances antitumor 
immunity (Leach et al., 1996), although the underlying mechanism was not identified at that time. 
Blockade of PD-1 restored the effector function of exhausted T cells in murine and human chronic 
viral infection with lymphocytic choriomeningitis virus (LCMV) (Barber et al., 2006) and human 
immunodeficiency virus (HIV) (Day et al., 2006; Freeman et al., 2006), respectively. Tumor cells 
upregulate PD-L1 on their surface as an immune escape mechanism (Dong et al., 2002; Hamanishi 
et al., 2007). Hypoxia, a general condition in many tumors, supports the recruitment of Tregs while 
stimulating the production of adenosine, which lowers CD8+ T cells activity (Facciabene et al., 
2011).  
 
3.3 Exploiting the immune system to control cancer 
 
With hindsight, the first immunotherapy was performed by William Coley in 1890s, a New York 
surgeon, who mainly operated patients with sarcoma. He observed remission in a cancer patient 
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upon development of erysipelas, a severe skin infection with Streptococcus pyogenes. 
Subsequently, Coley injected cancer patients with heat-killed S. pyogenes plus Serratia 
marcescens, a mixture called Coley’s toxin, and observed remission in some cases (Coley, 1891). 
Helen Coley Nauts, Coley’s daughter, later tabulated around 1000 patients treated by the father. 
She noticed that 500 of these cases showed near-complete remission (Nauts and McLaren, 1990). 
Despite the success of Coley’s toxin, it met criticism at that time and it suffered the pressure from 
the developing fields of radiotherapy and chemotherapy.  Nevertheless, Coley’s studies inspired the 
use of bacille Calmette-Guerin (BCG) as immunotherapy, still in use as the most effective 
treatment against superficial bladder cancer (Dranoff, 2004; Herr et al., 1995). 
To date, different immunotherapeutical approaches are in clinical trials and some have been 
recently approved in multiple countries. These include passive therapies such as antibodies or T 
cells targeting tumor cells as well as active therapies that aim to stimulate the patient’s immune 
system such as immunization, DC activation and blocking co-inhibition (checkpoint blockade). 
The problem of insufficient T cell priming or a suboptimal repertoire in the context of cancer can 
be circumvented by adoptive transfer of properly activated, high-affinity T cells. These include the 
adoptive transfer of in vitro activated and expanded, autologous tumor-infiltrating lymphocytes 
(TILs) together with IL-2 (Dudley et al., 2002), T cells activated with defined melanoma tumor 
antigens (Hunder et al., 2008), T cell transduced with high-affinity TCRs that specifically 
recognize TAAs (Morgan et al., 2006) and T cells transduced with chimeric antigen receptors 
(CARs) recognizing tumor-specific cell surface proteins that are composed of hybrid 
immunoglobulin light chains with endo-domains of T cells signaling molecules (Kalos et al., 
2011). These approaches have shown remarkable clinical responses especially using CD19- or 
CD20-specific T cells to treat lymphomas. 
Cancer vaccines intend to treat existing maligancies or prevent their formation. The vaccine against 
human papilloma virus (HPV) is the most successful cancer vaccine to date that works 
prophylactically but also showed efficacy when used as a therapeutic vaccine (Kenter et al., 2009) 
in patients with cervical cancer and vaginal neoplasias. The fact that the vaccine is based in a viral 
antigen may explain the efficacy. Another, less successful, example is Provenge (a treatment 
approved by the FDA in 2010 for metastatic prostate cancer, sipuleucel-T), which is a preparation 
of patient’s peripheral blood-derived APCs, loaded with a fusion protein of granulocytes-
macrophage colony stimulating factor (GM-CSF) and prostatic acid phosphatase (PAP). Upon 
injection the GM-CSF-activated APCs in the preparation should present PAP to patient’s T cells 
inducing their activation and proliferation (Kantoff et al., 2010). Treatment with a vaccine 
consisting of modified gp100 peptide (a melanocyte-specific protein) plus IL-2 resulted in 
increased survival of melanoma patients when compared to IL-2 alone (Schwartzentruber et al., 
2011). The principle for the above-mentioned vaccines is the combination of a known tumor 
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antigen and a factor to stimulate APCs or T cells. Unfortunately, characterized antigens are not 
available for many tumors, so this approach is not always applicable.  
Mature DCs are the most potent cells for stimulation of memory and naive T cells. The 
administration of ligands for TLRs have shown potent anticancer effect against established tumors 
in both mice and humans (Krieg, 2007). For example, local application of the TLR7 agonist 
Imiquimod to superficial basal cell carcinoma resulted in cure in 80-90% of cases (Schulze et al., 
2005). However, systemic administration of Imiquimod in patients with more advanced cancers has 
not resulted in the same degree of success (Dummer et al., 2008), nor was it proven that DC 
activation indeed was crucial to the therapeutic efficicacy. Despite their limited clinical success as 
monotherapies, the ability of TLR agonists to activate DCs makes them good candidates for 
combination with peptide/protein vaccines (Speiser et al., 2005) or with chemotherapy that 
presumably increases the presentation of tumor antigens (Guha, 2012). DC maturation can 
efficiently be achieved by agonistic anti-CD40 antibodies (Sarawar et al., 2001; Schoenberger et 
al., 1998) and such antibodies showed potent anti-tumor effects in several mouse models. However, 
anti-CD40 used as monotherapy showed only modest clinical activity in cancer patients (Advani et 
al., 2009). In addition, anti-CD40 showed considerable side effects in patients and therefore, the 
development of therapies based on anti-CD40 lags behind that of other immunotherapies.  
Nowadays, the development of a new class of immunotherapies has become possible because of a 
better understanding of T cell function and activation. T cell actvation is tightly regulated by 
inhibitory receptors such as CTLA-4 and PD1 in order to avoid unadequately strong immune 
responses (Fourcade et al., 2012; Wherry, 2011). The first antibody that targets one of the 
inhibitory receptors on T cells, CTLA-4, was approved by the FDA for the treatment of 
metastasized melanoma in 2010 (Ipilimumab or Yervoy) and caused an explosion of the field. It is 
not exactly understood how anti-CTLA-4 works, but recent preclinical data suggest selective 
depletion of tumor-associated Tregs as a mechanism (Simpson et al., 2013). Tumors frequently 
express the ligands for PD-1, PD-L1 and PD-L2 and this expression can be induced by IFN-γ 
(Twyman-Saint Victor et al., 2015). PD1 ligation interferes with TCR signaling (Greenwald et al., 
2005). Blockade of PD1/PDL1 axis showed impressive results in the clinics for the treatment of 
different tumor types (Powles et al., 2014; Topalian et al., 2012). Since PD1 and CTLA-4 are 
interfering with different pathways, in 2013 a clinical trial with the combination of anti-CTLA4 
and anti-PD1 started in melanoma patients that showed tumor regression in 50% of the patients 
(Wolchok et al., 2013). Also the combination of checkpoint blockade with cytokines seems 
promising. For example, the combination of anti-CTLA-4 with IL-12 induced regression of 
established gliomas in mice (Vom Berg et al., 2013) and a clinical trial is now being planned. 
Injection of IL-2/anti-IL-2 immune complexes selectively stimulates effector T cells without 
promoting Treg proliferation (Krieg et al., 2010) and resulted in control of B16 melanomas. This 
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effect was further improved if anti-CTLA-4 was added to the therapy. A clinical trial with 
melanoma patients using this combination is planned. 
Despite the clinical efficacy of checkpoint blockade, only a proportion of patients respond. Recent 
data show that especially patients with highly mutated tumors respond well, suggesting that 
mutations result in the expression of novel epitopes that are more immunogenic (Gubin et al., 2014; 
Kreiter, 2014). Furthermore, de novo priming rather than boosting pre-existing immunity seems a 
major consequence of immunotherapy (Bransi et al., 2015; Rizvi et al., 2015; Schumacher and 
Schreiber, 2015). 
Taken together, the field of cancer immunotherapy is rapidly evolving because of major 
achievements in recent years. Many trials are currently ongoing in which different 
immunotherapies are combined with each other or with standard therapies such as chemo- or 
radiotherapy. 
 
4. Radiotherapy 
 
4.1 Radiotherapy induces lethal DNA damage 
 
In the late 19th century the discovery of ionizing radiation was awarded with three Nobel prizes. In 
1948 the first radiation machine (cobalt source) was built and the first cancer patients were treated 
6 months after (Grubbe, 1946). The clinical efficacy of radiotherapy became quickly apparent and 
research concentrated on achieving maximal efficacy with minimal side effects since then (Thariat 
et al., 2013). Technological advancements allowed moving from the first megavoltage linear 
accelerator X-rays machine to the computer-modulated external beam radiotherapy (ERBT), the 
stereotactic body radiotherapy (SBRT), and finally high-dose radiotherapy and proton therapy 
(Allen et al., 2012). Nowadays, the field is moving towards hypofractionated radiotherapy, 
meaning application of radiation at high doses in fewer fractions (Vaidya et al., 2010). 
The efficacy of radiotherapy was thought to rely on its capacity to damage nucleic acids, protein 
and lipids, which is amplified by the radiation-mediated production of free radicals. Double-strand 
breaks (DSBs) and single-strand break (SSBs) are the most frequent types of damage to which 
cancer cells are more susceptible than normal tissue because of frequent mutations in DNA repair 
pathways (Begg et al., 2011; Giusti et al., 1998; Negrini et al., 2010). Cells exposed to ionizing 
radiation can undergo apoptosis, necrosis, mitotic catastrophe, autophagy and senescence. The type 
of cell death strictly depends on the cell type, the dose delivered, the cell cycle phase, the redox 
state and the DNA repair capacity of the target cell (Eriksson and Stigbrand, 2010; Golden et al., 
2012). Although the type of cell death matters to the immune system (Kroemer et al., 2013), this 
issue is not well investigated yet. 
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4.2 Radiotherapy stimulates tumor-specific immunity 
 
Recent evidence demonstrated that the direct killing of tumor cells is not the only mode of action of 
radiotherapy. It is now clear that radiotherapy-induced immunogenic cell death (ICD) and the 
stimulation of tumor-specific immunity are integral parts of its therapeutic efficacy (Apetoh et al., 
2007; Formenti and Demaria, 2012; Gupta et al., 2012; Sharma et al., 2013). 
Numerous studies highlighted different mechanism by which radiotherapy can overcome some of 
the major stumble stones described above.  
Studies showed that radiotherapy increases the amount and variety of tumor-associated antigens 
expressed by tumor cells, permitting APCs like DCs to prime T cells for specific recognition and 
killing of tumor cells (Sharma et al., 2013). Furthermore, radiation increases the expression of 
MHC class I molecules by tumor cells in vivo and in vitro, which makes them visible to CD8+ T 
cells (Reits et al., 2006; Sharma et al., 2013). Moreover, DCs recognize calreticulin exposed on the 
surface of tumor cells upon radiation as an eat-me signal (Obeid et al., 2007). It has been reported 
that radiotherapy leads to the release of high-mobility group box 1 (HMGB1) by irradiated tumor 
cells. HMGB1 is a potent DAMP that sustains DCs activation through activation of TLR-4 leading 
to an efficient T cell response (Apetoh et al., 2007). Radiation induces DCs maturation (Gupta et 
al., 2012) and increases the trafficking of DCs towards the draining lymph nodes, where they 
present the antigen to the T cells (Lugade et al., 2005). The infiltration of CD8+ T cells in the tumor 
is also enhanced by radiotherapy and it stimulates the production of type I and II IFNs, thus 
enhancing cross-presentation (Fuertes et al., 2011; Gupta et al., 2012; Lim et al., 2014). The tumor 
microenvironment also undergoes changes upon radiotherapy. Tumor-associated blood vessels are 
normalized upon radiotherapy, facilitating the infiltration of immune effectors (Huang et al., 2013). 
Radiotherapy causes the loss of lymphatic vessels and it impaires their function (Avraham et al., 
2010). 
Nevertheless, radiotherapy has also immunosuppressive effects. Radiation causes the production of 
ROS that amplify the inflammatory cascade (Valerie et al., 2007) and may result in tumor-
promoting chronic inlfmmation. Tregs increase upon radiotherapy and contribute to tumor 
development and radioresistance (Formenti and Demaria, 2013). In addition, it has been reported 
that radiotherapy leads to an increased production of co-inhibitory molecules like PD-L1 on tumor 
cells upon RT (Deng et al., 2014).  
The net impact of radiotherapy on tumor-specific immunity may depend on the therapeutic 
protocol, but data are limited and conflicting. For example, it has been suggested that high-dose 
radiotherapy is more potent in inducing immune-responses than low-dose radiotherapy (Lee et al., 
2009). Further studies are needed to clarify the effects of different radiotherapy protocols. In 
contrast, lower doses seemed to better synergize with anti-CTLA-4 (Dewan et al., 2009). 
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Taken together, radiotherapy is well established in the clinics and responsible for about 40% of 
cancers that are cured. Despite this, fundamental knowledge of pathways affected by radiotherapy 
and precise understanding of the effects on tumor-specific immunity are scarce. Also comparisons 
between different radiotherapy protocols, especially between hypo- and hyperfractionated 
radiotherapy, in which clinical and biological parameters are linked are hardly performed. 
We reasoned that some radiotherapy-induced pathways will support tumor-specific immunity and 
thus clinical efficacy, whereas others will suppress. Specific inferference with such pathways may 
increase the efficacy of radiotherapy and will provide a rational basis for novel combination 
therapies.  
 
Therefore, my work has following aims: 
1. Investigation of the upstream mechanism leading to the radiotherapy-mediated tumor-
specific immune reponse  
2. Characterization of radiotherapy-induced changes in the tumor-associated lymphatic 
vessels 
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SUMMARY
Radiotherapy induces DNA damage and cell death,
but recent data suggest that concomitant immune
stimulation is an integral part of the therapeutic ac-
tion of ionizing radiation. It is poorly understood
how radiotherapy supports tumor-specific immunity.
Here we report that radiotherapy induced tumor cell
death and transiently activated complement both in
murine and human tumors. The local production of
pro-inflammatory anaphylatoxins C3a and C5a was
crucial to the tumor response to radiotherapy and
concomitant stimulation of tumor-specific immunity.
Dexamethasone, a drug frequently given during
radiotherapy, limited complement activation and
the anti-tumor effects of the immune system. Overall,
our findings indicate that anaphylatoxins are key
players in radiotherapy-induced tumor-specific im-
munity and the ensuing clinical responses.
INTRODUCTION
It is now well accepted that the immune system can control
tumors (Schreiber et al., 2011). For example, there is a positive
correlation between tumor infiltration by effector T cells and sur-
vival (Fridman et al., 2011), and the risk to develop cancer is
increased in immunosuppressed patients (Dunn et al., 2006),
and dormant tumors are kept in check by the adaptive immune
system (Koebel et al., 2007). Despite the presence of tumor-spe-
cific immunity in many cancer patients, complete rejection of
clinically apparent tumors by the immune system is rare, pre-
sumably due to mechanisms that locally inhibit tumor-specific
protective immunity (Schreiber et al., 2011). The clinical efficacy
of so-called checkpoint blockade, antibodies that target co-
inhibitory molecules such as CTLA-4 or PD-1, underscores the
potential of tumor-specific immunity (McDermott and Atkins,
2013; Mellman et al., 2011).
Radiotherapy is a standard treatment for cancer that induces
irreversible damage to DNA, thus targeting mainly rapidly
dividing cells (Prise and O’Sullivan, 2009). Although radiotherapy
was considered an immunosuppressive treatment (Merrick et al.,
2005), there is accumulating evidence that it supports local
tumor-specific immunity (Apetoh et al., 2007; Matsumura et al.,
2008) and, in fact, that immune activation might be an integral
part of radiotherapy (Formenti and Demaria, 2012; Gupta et al.,
2012; Ma et al., 2010; Sharma et al., 2013). This is clinically rele-
vant because tumor-specific immunity can target dormant
lesions (Postow et al., 2012) that are presumably insensitive to
radiotherapy. Several studies have addressed the question
of how radiotherapy supports tumor-specific immunity, and
various factors were suggested, including increased presence
or function of tumor-infiltrating CD8+ T cells (Gupta et al.,
2012; Lugade et al., 2005; Takeshima et al., 2010), type I inter-
feron (IFN) resulting in enhanced antigen cross-presentation
(Burnette et al., 2011; Fuertes et al., 2011), increased expression
of major histocompatibility complex (MHC) class I glycoproteins
and tumor-associated antigens (Reits et al., 2006), and matura-
tion of tumor-associated dendritic cells (DCs) (Gupta et al.,
2012), however, an initial event has not been identified.
We therefore performed an unbiased analysis of immune
response-related transcripts after radiotherapy in a preclinical
model and noted a strong and transient upregulation of genes
associated with the complement pathway. This was unexpected
as complement was described as tumor-promoting (Markiewski
et al., 2008; Pio et al., 2014), although other studies have shown
that complement supports adaptive immunity (Farrar and Sacks,
2014; Kopf et al., 2002; Lalli et al., 2007; Liszewski et al., 2013;
Strainic et al., 2013). Becauseweobserved similar changes in hu-
man tumor samples, we investigated the impact of complement
on the anti-tumor immune response following radiotherapy.
RESULTS
Radiotherapy Induces Complement Activation
To identify the initial event in radiotherapy-induced tumor-spe-
cific immunity, we performed an unbiased analysis of immune
Immunity 42, 1–11, April 21, 2015 ª2015 Elsevier Inc. 1
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response-related transcripts after radiotherapy. Local irradiation
with a single dose of 20 Gy significantly reduced progression of
B16F10-OVA tumors in C57BL/6 mice (Figures 1A and 1B).
Because transplantable mouse tumors only allow for a short
therapeutic window, radiotherapy must be applied as a single
high dose (Lugade et al., 2005). To dissect which pathways are
crucial to radiotherapy-induced stimulation of the immune
response, we quantified immune response-related transcripts
in tumors at different time points 4, 24, 96, and 168 hr after local
irradiation (Figures 1C and S1A). We observed an upregulation of
the complement system (represented in this panel only by C3)
and the inflammation cascade at 4 and 24 hr, whereas both path-
ways were downregulated at 96 and 168 hr after irradiation (Fig-
ure 1C). Because 20 Gymight be of limited clinical relevance, we
performed the same analysis 24 hr after irradiation with a single
dose of 5 Gy and observed a similar transcriptional upregulation
(Figure S1B).
C3 is the central protein of the complement cascade at which
all three known pathways (classical, alternative, and lectin)
converge and which gives rise to various bioactive components
(Markiewski and Lambris, 2009). Because complement might be
tumor-promoting (Markiewski et al., 2008; Markiewski and
Lambris, 2009; Pio et al., 2014), we investigated whether radio-
therapy-induced upregulation of complement supported or
antagonized the efficacy of this treatment. We first quantified
four different complement-related transcripts in response to
radiotherapy: C3, C1s, Masp2 and Cfb. The classical and alter-
native pathways are the main pathways induced by radiotherapy
on the transcriptional level (Figures 1D and S1C). Because
NF-kB, JAK, and STAT transcriptional pathways (Chen et al.,
2011; Fukuoka et al., 2013; Hasegawa et al., 2014; Huang
et al., 2002), as well as S100 calcium-binding proteins A8 and
A9 (S100A8, S100A9) (Schonthaler et al., 2013) are involved in
the transcription of complement factors, we analyzed such path-
ways by immuno-blot and found an increased production of
STAT 1, STAT 2, STAT 3, NF-kB, and JAK and increased phos-
phorylation of STAT 2, STAT3, and JAK (Figure S1D) 4 hr, but not
Figure 1. Radiotherapy Results in Transient Upregulation and Acti-
vation of Complement in Murine and Human Tumors
(A–E) Mice were injected with B16F10-OVA cells and received radiotherapy
12 days later. (A) Tumor growth curves, (n = 5 mice per group). Representative
data from three independent experiments are shown. (B) Tumor weight
(day 20). (C) Heatmaps of transcripts were created using the log2 value of
the fold increase of irradiated compared to untreated tumors at different
time points after radiotherapy, (n = 6 mice per time point). Representative data
from two independent experiments are shown. (D) Relative expression of C3
mRNA in tumors at different time points after radiotherapy. The data show the
mean ± SD of triplicates from three independent analyses. Radiotherapy, RT.
(E) Immunofluorescence of irradiated and untreated tumors. Sections were
stained with an antibody recognizing C3b, iC3b, and C3c (green), CD31 for
blood vessels (red), and DAPI (blue). Scale bars represent 100 mm (n = 6 mice
per group). Representative images from two independent experiments are
shown.
(F and G) Patient biopsies were collected before and 24–36 hr after radio-
therapy (1.5–2 Gy; upper panel) or only after radiotherapy (lower panel).
Quantification of complement transcripts by qPCR. Data show the mean ± SD
of triplicates from two independent analyses (upper panel). (G) Quantification
of C3-a and -b subunits by immuno-blot.
Data are shown as mean ± SD. *p < 0.05, **p < 0.005, ***p < 0.0005 by Stu-
dent’s t test (A, B, and F) or two-way ANOVAwith the Bonferroni correction (D).
See also Figure S1.
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24 hr, after radiotherapy. Transcripts of S100a8 and S100a9
were unaffected (data not shown).
To show that these translated in different complement factor
amounts, we analyzed the tumors prior to and after radiotherapy
by immunofluorescence (Figure S1E) and by immuno-blot (Fig-
ure S1F). Because C1q and Factor B are more abundant
compared to mannose-binding lectin C (MBL-C), these results
confirmed our qPCR data (Figure S1C). We analyzed the activa-
tion status of complement and found deposition of fragments
derived from C3 cleavage (C3b, iC3b, and C3c) 24 hr after radio-
therapy in the proximity of (green fluorescence) or associated
with (yellow fluorescence) blood vessels (Figure 1E). Similarly
to C3 cleavage products, we observed C1q and Factor B mainly
associated to blood vessels, whereas MBL-C showed a mark-
edly different pattern of deposition. We obtained similar results
using B16F10 cells, both at the transcriptional (data not shown)
and protein level (Figure S1G). We confirmed radiotherapy-
induced complement activation by immuno-blotting using an
antibody recognizing C3 plus its fragments C3b, C3c, and
C3dg (Figure S1H). Because deposition of C3b, iC3b, and C3c
was not detected at other time points besides 24 hr after radio-
therapy, this suggests that radiotherapy-induced complement
activation is a rapid and transient response.
We analyzed the expression of complement-related tran-
scripts and proteins in paired human tumors that were collected
before and 24–36 hr after a single, low dose of radiotherapy (1.5
or 2 Gy) and detected upregulated expression (Figure 1F) and
activation of complement (Figure 1G). To exclude that taking
the first biopsy prior to radiotherapy rather than radiotherapy
was responsible for complement activation, we analyzed addi-
tional four biopsies that were taken 24–36 hr after irradiation
with 1.5–2 Gy but without previous intervention. The amounts
of complement transcripts were comparable to those after radio-
therapy in the paired samples, excluding this option (Figure 1F).
Together, we found that radiotherapy induces transient, local
production, and activation of the classical and alternative com-
plement pathway in both human and murine tumors.
Therapeutic Efficacy of Radiotherapy Depends on C3a
and C5a
To investigate the impact of complement activation on therapeu-
tic efficacy, we applied radiotherapy to tumor-bearing C3!/!
mice. Because tumors grew more slowly in C3!/! mice (Figures
2A and S2A) (Markiewski et al., 2008; Qing et al., 2012), C3!/!
and C57BL/6 mice were irradiated at two different time points,
i.e., 13 (Figure 2A) or 17 days (Figure S2B) after tumor injection.
Comparison of C57BL/6 mice irradiated at day 13 (Figure 2A, left
panel) with C3!/! mice irradiated at day 17 (Figure S2B, right
panel) shows the response of tumors with a similar size (36–
40 mm2) at the time point of irradiation. Radiotherapy was not
efficient in C3!/!mice irrespective of the day of therapy (Figures
2A, S2A, and S2B), suggesting that complement activation is
crucial to efficacy.
Anaphylatoxins (C3a and C5a) modulate adaptive immunity
(Schmudde et al., 2013; Strainic et al., 2013). As we observed
higher local amounts of C3a and C5a (Figure S2C) and their
receptors (Figures S2D) upon radiotherapy, we investigated
their role in the response to radiotherapy using C3ar1!/!,
C5ar1!/!, and C3ar1!/!C5ar1!/! mice. As these mice were
only available on a BALB/c background, we confirmed that
radiotherapy resulted in local complement activation (Fig-
ure S2E), showing that radiotherapy-induced complement
activation is a general phenomenon independent of the strain
or tumor cell line used. Similar to C3!/! mice, C5ar1!/!,
Figure 2. C3a and C5a Are Crucial to the Therapeutic Efficacy of
Radiotherapy
(A) Control and C3!/!mice were injected with B16F10-OVA cells and received
radiotherapy 13 days later. Growth curves, (n = 5 mice per group). Represen-
tative data from two independent experiments are shown. Radiotherapy, RT.
(B) BALB/c, C3ar1!/!, C5ar1!/!, and C3ar1!/!C5ar1!/! were injected with
CT26 cells and received radiotherapy 13 days later. Tumor growth curves
(BALB/c n = 5 mice per group; C3ar1!/!, C5ar1!/!, and C3ar1!/!C5ar1!/!
n = 8mice per group). Representative data from two independent experiments
are shown.
(C) Mice were injected with B16F10-OVA cells and received radiotherapy
12 days later. SB290157 was administered at 2 mg/kg to block C3aR1 and
anti-C5aR1 mAb 20/70 or an isotype control at 0.6 mg/kg to block C5aR1
(administered every second day starting on day 12 until day 19). (n = 5mice per
group).
Data are shown as the mean ± SD. **p < 0.005, ***p < 0.0005, ****p < 0.00005
by two-way ANOVA with the Bonferroni correction. See also Figure S2.
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C3ar1!/!, and C3ar1!/!C5ar1!/! mice showed no significant
impact of radiotherapy on tumor progression, whereas BALB/c
mice did (Figures 2B, 2C, and S2F). To avoid the issue of inherent
different tumor growth rates in various genetically ablated
strains, we blocked C3aR with an antagonist (C3aRA,
SB290157) or C5aR with a monoclonal antibody (20/70) (Baelder
et al., 2005) just before applying radiotherapy to tumor-bearing
C57BL/6 mice. This treatment blocked the improved antitumor
effect of radiotherapy (Figures 2D and S2G), which is in line
with the results observed in C3!/!, C3ar1!/!, C5ar1!/!, and
C3ar1!/!C5ar1!/! mice. These data suggest that radiotherapy
induces the intratumoral generation of anaphylatoxins, which
are crucial to the therapeutic efficacy.
Radiotherapy-Induced Cell Death Locally Activates
Complement
Despite the fact that complement deposition was observed in
the vicinity of blood vessels, we failed to detect activated
complement in serum irrespective of whether mice received
radiotherapy or bore a tumor (Figure 4A). This excludes that
Figure 3. Radiotherapy-Induced Tumor
Cells Death Activates Complement
(A and B) B16F10-OVA cells were irradiated in vitro
with 20 Gy or left untreated. Serum from C57BL/6
or C3!/! mice was added to the cultures immedi-
ately after irradiation and C3 cleavage products
were analyzed 4 and 24 hr later in the supernatants
by immuno-blot using a polyclonal anti-C3 anti-
body (n = 3 mice per group). Representative data
of two independent experiments are shown. (B)
Relative intensities were calculated using Bio1D
software. Radiotherapy, RT.
(C) Ultrastructural analysis of tumor response to
radiotherapy. B16F10-OVA tumors were isolated
from mice prior to and different times after radio-
therapy. Fixed tumor tissue was epon embedded
and analyzed by EM. Shown are images of tumor
tissues before (0 h), 1, 4, and 18 hr after radio-
therapy. Left column, overview; Right column,
zoom-in of region indicated in left image. Bar in-
dicates magnification. N, nucleus; M, mitochon-
drion; black arrow, cell boundaries; F, fat bodies;
C, collagen; *, melanosomes.
(D and E) B16F10-OVA cells were irradiated in vitro
with 20 Gy or left untreated. Serum from Rag1!/!
mice was added to the cultures immediately after
irradiation and C3 cleavage products were
analyzed as described in (A), (n = mice 3 per
group). (E) Relative intensities were calculated
using Bio1D software.
Data in (B) are shown as the mean ± SD. *p < 0.05,
**p < 0.005, by two-way ANOVA with the Bonfer-
roni correction.
radiotherapy or a local tumor results in
systemic activation of complement. Local
radiotherapy results in apoptosis (Wang,
2008), mitotic catastrophe, and necrosis
(Eriksson and Stigbrand, 2010), all of
which can be potent activators of comple-
ment (Basu et al., 2000; Kemper et al.,
2008; Markiewski and Lambris, 2007). We first evaluated the
possibility of direct complement activation by radiation and
exposed serum from C57BL/6 or C3!/! mice in vitro to a single
dose of 20 Gy or left them untreated and analyzed sera 4 and
24 hr after irradiation by immuno-blot. We did not detect any sig-
nificant changes upon irradiation (data not shown). To investi-
gate whether irradiated tumor cells can activate complement,
we either or not exposed B16F10-OVA cells in vitro to a single
dose of 20 Gy. Immediately after irradiation, 10-fold diluted
serum from C57BL/6 mice or C3!/! mice was added to irradi-
ated or untreated B16F10-OVA cells. Complement activation
was detected in the supernatants 24 hr after radiation. Because
the culture serum was from C3!/!mice, the complement should
have been derived from the tumor cells (Figures 3A and 3B).
To identify the mode of tumor cell death upon a single dose of
20 Gy, we performed electron microscopy (EM) on B16F10-OVA
tumors isolated at different time points after radiotherapy as indi-
cated (Figure 3C). The tissue isolated before radiation showed
normal nuclei, cell boundaries, intracellular organelles, and me-
lanosomes (the dark vesicular structures) illustrating healthy
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tumor tissue. Already 1 hr after radiation, the first signs of radia-
tion damagewere detected in the formof extensive vacuolization
of tumor cells with normal nuclei and cell boundaries. Already
4 hr after radiation, cell boundaries were dissolved and cellular
content fragmented. Mitochondrial structures (M) were swollen
and did not show normal cristae. This did not change any further
between 4 and 18 hr after radiotherapy. We did not observe any
nuclear fragmentation and apoptotic bodies; rather, the irradi-
ated tissue showedmarked fields of necrosis withmany intracel-
lular materials now entering the extracellular space.
Because immunoglobulin M (IgM) binds to necrotic cells,
which results in complement activation (Ciurana et al., 2004;
Quartier et al., 2005), we performed the experiment described
above using serum from Rag1!/! mice. We observed reduced
complement activation in supernatants containing Rag1!/!
serum (Figures 3D and 3E), suggesting that IgM binding to
necrotic cells contributes to radiotherapy-induced complement
activation. This suggests that necrotic tumor cells express or
secrete factors that activate complement.
Microenvironmental Complement Is Produced by
Immune Cells
Hepatocytes are the main source of complement proteins,
but also extra-hepatic tissues and immune cells can produce
them (Farrar and Sacks, 2014; Kolev et al., 2014; Pio et al.,
2014; Strainic et al., 2008). To define the source of radio-
therapy-induced, tumor-associated complement, we generated
C3!/!/WT, WT/C3!/!, WT/WT, and C3!/!/C3!/! bone
marrow chimeras. B16F10-OVA bearing chimeras received
radiotherapy or not and tumors were processed 24 hr later.
We detected high amounts of activated complement in
C3!/!/WT and WT/WT mice and less in WT/C3!/! mice.
The low amount of complement detected in irradiated tumors
in C3!/!/C3!/! mice is presumably tumor-derived (Figures
4B and 4C). This is in agreement with the detection of basal
expression of complement-related transcripts in cultured
B16F10-OVA tumor cells and an increased release of comple-
ment proteins by B16F10-OVA cells upon in vitro irradiation
(Figures 3A, 3B, and 4C). These experiments suggest that a large
fraction of radiotherapy-induced, tumor-associated comple-
ment is produced systemically, with a contribution of local pro-
duction by immune and tumor cells.
Radiotherapy-Induced DC Activation Depends on
Anaphylatoxins
Because several immune cells can produce complement com-
ponents (Li et al., 2007; Strainic et al., 2008), which are essential
for full functional development of antigen-presenting cells (APCs)
and T cell responses (Peng et al., 2009; Strainic et al., 2008), we
investigated which immune cells produce complement or ana-
phylatoxin receptors in irradiated tumors. We sorted DCs,
CD8+ T cells, CD4+ T cells, and other CD45.2+ cells from irradi-
ated and untreated tumors (Figure S3A) and quantified the com-
plement factor related transcripts C3, C1s, Masp2, Cfb, C3ar1,
and C5ar1 by qPCR. Because the impact of radiotherapy on
tumor-associated DCs and T cells is apparent after 24 hr and
5–7 days, respectively (Gupta et al., 2012), we harvested tumors
at these time points after radiotherapy exposure. DCs showed
increased expression of C3, Cfb, C3ar1, and C5ar1 24 hr and
168 hr after radiotherapy (Figure 5A). We failed to detect expres-
sion of C1s and Masp2 transcripts by DCs. The other CD45.2+
cells (mainly containing macrophages) showed upregulated
C5ar1 but no other complement-related transcripts at 168 hr
after radiotherapy (Figure S3B).
Recent studies demonstrate that complement factors, in
particular anaphylatoxins, directly bind to their receptors on
DCs thereby supporting their maturation, which then induces
T cell effector activation (Li et al., 2007; Peng et al., 2009; Strainic
et al., 2008). Furthermore, we showed previously that radio-
therapy-induced activation of tumor-associated dendritic cells
locally supports the function of tumor-specific CD8+ T cells
Figure 4. Radiotherapy-Induced, Tumor-Associated Complement Is
Mainly Liver-Derived but Partially Produced Locally
(A) Measurement of complement activation by immuno-blot in pooled blood
samples from naive, tumor-bearing, and irradiated tumor-bearing mice (24 hr
after radiotherapy), (n = 3 mice per group). C3 cleavage products were de-
tected using a polyclonal anti-C3 antibody. Radiotherapy, RT.
(B and C) Bone-marrow chimeras were injected with B16F10-OVA cells and
received radiotherapy 13 days later. Tumors were collected 24 hr after
radiotherapy (B) Immunofluorescence of irradiated and untreated tumors.
Sections were stained with an antibody recognizing C3b, iC3b, and C3c
(green), CD31 for blood vessels (red) and DAPI (blue). Scale bars represent
100 mm. Representative images from two independent experiments are shown
(n = 4 mice per group). (C) C3 cleavage products in the tumors were analyzed
by immuno-blot using a polyclonal anti-C3 antibody, (n = 3 mice per group).
Relative expression measured by Bio-1D software. Representative data from
two independent experiments are shown.
Data in (C) are shown as the mean ± SD. *p < 0.05, ***p < 0.0005 by two-way
ANOVA with the Bonferroni correction.
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and that this is crucial to therapeutic efficacy (Gupta et al., 2012).
Therefore, we analyzed the activation status of DCs upon irradi-
ation in C3!/! and in C57BL/6 mice 2 days after radiotherapy.
DCs were equally present in untreated and irradiated tumors of
complement-proficient and -deficient mice, however, DC activa-
tion as measured by surface expression of CD70 and CD86 (Kel-
ler et al., 2008) was observed only in irradiated C57BL/6, but not
in C3!/! mice (Figure 5B). These results were confirmed using
C3ar1!/!, C5ar1!/!, and BALB/c mice (Figure 5C). Thus, radio-
therapy induces upregulation of anaphylatoxins, and their recep-
tors in tumor-associated DCs controls radiotherapy-induced DC
activation.
Radiotherapy-Induced CD8+ T Cell Activation Depends
on Anaphylatoxins
T cells express complement components and anaphylatoxin re-
ceptors that are critical to T cell co-stimulation (Liszewski et al.,
2013; Strainic et al., 2008). CD8+, but not CD4+ T, cells upregu-
lated C3 and the anaphylatoxin receptors slowly at 168 hr, but
not at 24 hr, after radiotherapy (Figures 6A and S3C), whereas
C1s andMasp2were undetectable. C5aR1 and C3aR1 signaling
during cognate interaction between DCs and CD4+ T cells pro-
motes IFN-g production (Liu et al., 2008) and counteracts the
development of FoxP3+ regulatory T cells (Strainic et al., 2013).
We therefore analyzed the impact of radiotherapy on expression
of Ifng and Foxp3 and observed a strong upregulation of
Ifng in CD8+ T cells 168 hr after the treatment (Figure 6A),
but no changes of Foxp3 within the CD4+ T cell compartment
(data not shown).
To investigate the in vivo relevance of those observations,
we analyzed the infiltrate in tumors from BALB/c and
C3ar1!/!C5ar1!/! mice by flow cytometry 168 hr after radio-
therapy. Radiotherapy resulted in higher numbers of CD45.2+
and CD8+ T cells in tumors, which was independent of anaphy-
latoxins (Figure 6B). Radiotherapy had no effect on CD4+ T cell
numbers (Figures 6C and 6D). Therefore, it is unlikely that ana-
phylatoxins act as chemoattractants for T cells. We analyzed
the global IFN-g production by tumor-infiltrating CD8+ T cells
in situ. Therefore, we injected mice with Brefeldin A 4 hr
before euthanasia and measured intracellular IFN-g without
in vitro restimulation. IFN-g production by CD8+ T cells was
significantly increased in irradiated tumors in BALB/c, but not
C3ar1!/!C5ar1!/! mice compared to untreated controls (Fig-
ures 6C, S4A, and S4B). This presumably involves anaphyla-
toxin-mediated DC maturation (Strainic et al., 2013), although a
direct activity of anaphylatoxins on CD8+ T cells cannot
be excluded. In agreement with earlier data (Strainic et al.,
2013), we observed higher numbers of FoxP3+ T cells in
C3ar1!/!C5ar1!/! mice independent of radiotherapy (Figures
6D, S4C, and S4D). Flow cytometry results thus confirmed the
qPCR data on sorted cells (Figure 6A). We obtained similar
results using B16F10-OVA-bearing C57BL/6 mice in which
C3aR1 and C5aR1 were blocked (Figure S4E). A recent pub-
lication shows that blocking C3 improves the efficacy of fraction-
ated radiotherapy given as multiple daily fractions of 1.5 Gy
(Elvington et al., 2014), which is an apparent controversy with
our findings. We found that 53 1.5 Gy equally diminished tumor
growth as 13 20 Gy did. However, in contrast to a single high
dose, 53 1.5 Gy resulted in prolonged activation of complement
and did not support accumulation of CD8+ T cells nor their func-
tion in the tumor (Figures S4G–S4I).
To generate a complete immune cell profile related to
irradiation responses, we analyzed CD19+ B cells and found
low numbers (Figure S4F), regardless of radiotherapy or
blockade of C5aR1 and C3aR1. Tumors contained substantial
numbers of NK1.1+ cells that significantly increased upon
Figure 5. Radiotherapy Induces Upregula-
tion of Transcripts for Complement and
Anaphylatoxins Receptors by DCs and Is
Essential to Their Maturation
(A) Mice were injected with B16F10-OVA cells and
received radiotherapy 12 days later. DCs (CD45.2+
TCRb! CD11c+ MHC-IIhigh gated on live singlets)
were sorted from untreated and irradiated tumors
24 and 168 hr after radiotherapy. Complement-
related transcripts were quantified by qPCR (n = 5
mice per group). Radiotherapy, RT.
(B) Control and C3!/! mice were injected with
B16F10-OVA cells and received radiotherapy
12 days later. CD70 and CD86 expression on
tumor-associated DCs in irradiated (48 hr after
radiotherapy) and untreated tumors plotted as
geometric mean fluorescence intensity (gMFI).
(C) BALB/c, C3ar1!/!, and C5ar1!/! mice were
injected with CT26 cells and received radiotherapy
12 days later. DCs were analyzed as described
in (B).
(B and C) Each symbol represents an individual
mouse. Pooled data from two independent ex-
periments are shown. Data are shown as the
mean ± SD. *p < 0.05, **p < 0.005, ***p < 0.0005 by
two-way ANOVA with the Bonferroni correction.
See also Figure S3.
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radiotherapy and seemed independent of anaphylatoxin recep-
tor blockade. We observed very low numbers of NKp46+ cells
that remained similar in all four groups (Figure S4F). Thus,
following a single dose of 20 Gy, the DC-CD8-arm of the im-
mune system appears to be selectively activated in irradiated
tumors, which is essential for tumor control and depends on
complement.
Dexamethasone (DEX) is a glucocorticoid with anti-inflamma-
tory and immunosuppressive properties (Auphan et al., 1995). In
addition, it inhibits the activation of complement (Engelman
et al., 1995; Packard and Weiler, 1983). Given the important
role of complement in promoting adaptive immunity and sup-
porting the efficacy of radiotherapy, we treated mice with DEX
starting 1 day before radiotherapy. DEX treatment significantly
reduced the extent of local complement activation (Figure 7A)
and importantly, also the efficacy of radiotherapy (Figures 7B
and 7C).
Thus, radiotherapy-induced, local production of anaphylatox-
ins is essential to activation of DCs and protective effector
function of CD8+ T cells in the tumor and as such to therapeutic
efficacy.
Figure 6. Radiotherapy Induces Upregulation of Transcripts for
Complement and Anaphylatoxins Receptors by CD8+ T Cells and
Supports Tumor-Specific Immunity
(A) C57BL/6 mice were injected with B16F10-OVA cells and received radio-
therapy 12 days later. CD8+ T cells (CD45.2+ TCRb+ CD8+ gated on live sin-
glets) were sorted from untreated and irradiated tumors 24 and 168 hr after
radiotherapy. Complement-related transcripts were quantified by qPCR (n = 5
mice per group). Radiotherapy, RT.
(B–D) BALB/c and C3ar1!/!C5ar1!/! mice were injected with CT26 cells and
received radiotherapy 12 days later. Flow cytometric analysis was performed
7 days after radiotherapy. (B) The total number of infiltrating leukocytes
(CD45.2+), (C) CD8+ cells (left panel), and CD8+ T cells that produce IFN-g
in vivo (right panel), (D) CD4+ (left panel) and FoxP3+ CD4+ T cells (right panel)
were determined per gram tumor tissue. Mice were injected with Brefeldin A
4 hr before euthanasia.
Each symbol represents an individual mouse. Data are shown as the mean ±
SD. *p < 0.05, **p < 0.005, ***p < 0.0005 by two-way ANOVA with the Bon-
ferroni correction. See also Figure S4.
Figure 7. Dexamethasone Inhibits Complement Activation and
Reduces the Clinical Efficacy of Radiotherapy
(A–C) Mice were injected with B16F10-OVA cells and received radiotherapy
14 days later. DEX (0.3 mg/kg) was injected daily from day 12 until day 22,
(n = 6 mice per group). (A) Immunofluorescence of irradiated (24 hr) and
untreated tumors. Sections were stained with an antibody recognizing C3b,
iC3b, and C3c (green), CD31 for blood vessels (red), and DAPI (blue). Scale
bars represent 100 mm. Representative images are shown. (B) C3 cleavage
products in the tumors 24 hr after radiotherapy were analyzed by immuno-blot
using a polyclonal anti-C3 antibody. Relative expression measured by Bio-1D
software. Representative data are shown. (C) Tumor growth curves.
The data are shown as the mean ± SD. *p < 0.05 by two-way ANOVA with the
Bonferroni correction. Radiotherapy, RT.
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DISCUSSION
In this study, we have demonstrated that radiotherapy induces
an acute and transient local activation of complement, which is
pivotal for tumor-specific immunity and therapeutic efficacy.
Complement has traditionally been considered only to ‘‘comple-
ment’’ the action of the immune system in the antibody-mediated
defense against pathogens. The current appreciation is that
complement is involved in many different pathological pro-
cesses such as transplant rejection, autoimmunity, neurodegen-
eration, and cancer.
The role of complement in cancer is still confusing as the pro-
duction of complement-inhibiting proteins by tumor cells or
stroma has been suggested to promote tumor growth (Kolev
et al., 2011), whereas it is also proposed that complement in
the context of chronic inflammation promotes tumor growth,
migration and angiogenesis (Markiewski et al., 2008; Pio et al.,
2014). This is in line with a previous publication (Elvington
et al., 2014) showing increased efficacy of fractionated radio-
therapy when C3 was blocked. Repeated irradiation might thus
induce a chronic inflammatory response that interferes with pro-
tective adaptive immunity. In addition, the infiltrating T cells
might be killed by the next dose before they could execute their
anti-tumor effect. A different radiotherapy protocol that either
introduces a radiotherapy holiday of 7–10 days between the frac-
tions of radiotherapy or provides a single high-dose of radio-
therapy might be required to optimally support tumor-specific
immunity (Favaudon et al., 2014).
Pathogen- and damage-associated molecular patterns can
activate C1q, MBL, and the alternative complement pathway.
The latter can also be activated by spontaneous hydrolysis of
C3 or by non-complement proteins (Markiewski and Lambris,
2007). Furthermore, modified membranes of late apoptotic and
necrotic cells are potent activators of complement (Ricklin
et al., 2010). In fact, every disturbance of homeostasis or assault
might result in activation of complement (Kolev et al., 2014). Our
data suggest that factors released from necrotic tumor cells
upon radiotherapy are responsible for local complement activa-
tion. The leakiness of tumor-associated blood vessels (Carmeliet
and Jain, 2011) might further promote accumulation of comple-
ment in the tumor.
The liver is the main source of complement, but many comple-
ment components can be produced by a variety of tissues and
immune cells either constitutively or in response to stress (Kolev
et al., 2014; Li et al., 2007). For example, locally produced C1q
contributes to removal of apoptotic material and immune com-
plexes (Roumenina et al., 2011) and supports T cell responses
(Baudino et al., 2014). We have shown here that tumor-associ-
ated T cells, DCs, other CD45+ cells, as well as tumor cells can
be a source of anaphylatoxins and their receptors in response
to radiotherapy. It is plausible to consider that tumor-associated
stroma might also contribute to the production of complement
upon radiotherapy.
Sensing immune cell-derived complement during cognate in-
teractions between T cells and DCs is essential for development
of protective immunity (Lalli et al., 2007; Liszewski et al., 2013;
Peng et al., 2009; Strainic et al., 2008). Moreover, when signaling
through C3aR1 and C5aR1 is prevented during cognate interac-
tions, CD4+ T cells develop into FoxP3+ regulatory T (Treg) cells
instead of effectors (Strainic et al., 2013), in line with our obser-
vation that tumors contained more Treg cells in the absence of
anaphylatoxin receptor signaling. We found that tumor-associ-
ated DCs produced complement factors and upregulated the
expression of C3aR1 and C5aR1 upon radiotherapy, which
appeared to be essential for radiotherapy-induced DCs matura-
tion. It has been shown that anaphylatoxins directly can induce
DC maturation in vitro and that C3 upregulation precedes the
expression of IL-1, IL-12, and IL-23 (Strainic et al., 2008), sug-
gesting a direct effect of anaphylatoxins on DCs. DC maturation
is crucial to development and/or maintenance of T cell effector
function within the tumor and efficacy of radiotherapy (Gupta
et al., 2012), and indeed, tumor-infiltrating CD8+ T cells failed
to produce IFN-g after radiotherapy in the absence of signaling
through C3aR1 and C5aR1.
Given the importance of complement activation and immune
response following local radiotherapy, the administration of glu-
cocorticoids, anti-inflammatory, and immunosuppressive drugs
for managing post-radiation symptoms (Hempen et al., 2002;
Hughes et al., 2005) might have a modulating impact on the effi-
cacy of radiotherapy. Indeed, DEX given around the time of
radiotherapy significantly diminishes its efficacy, suggesting
that treatment with glucocorticoids or other anti-inflammatory
or immunosuppressive drugs might decrease the clinical
response of cancer patients to radiotherapy.
The stimulation of tumor-specific immunity by standard thera-
pies including radio- and chemotherapy has been documented
in several publications (Formenti and Demaria, 2012; Gupta
et al., 2012; Matsumura et al., 2008; Reits et al., 2006; Sharma
et al., 2013) and this phenomenonmight actually be of great clin-
ical importance: dormant metastases are intrinsically resistant to
standard treatments that mainly target rapidly dividing cells but
might still be susceptible to immune-mediated control (Koebel
et al., 2007). The abscopal effect—a situation in which not only
the irradiated tumor but also distant lesions show a clinical
response—can be explained as such. When radiotherapy is
combined with immune stimulation by anti-CTLA-4 antibodies,
the abscopal effect becomes readily apparent (Postow et al.,
2012; Verbrugge et al., 2014).
Our data expand the role of complement in the defense
against tumors. Tumor-specific immunity is unleashed by locally
produced anaphylatoxins in response to radiotherapy that acti-
vate DCs and then CD8+ T cells for optimal tumor control
following radiotherapy.
EXPERIMENTAL PROCEDURES
Mice and Cell Lines
C57BL/6, C3!/!, BALB/cJ, C5ar1!/!, C3ar1!/!, and Rag1!/! mice were pur-
chased from the Jackson Laboratory. C3!/! mice were on a C57BL/6.129S4
background; C3ar1!/! and C5ar1!/! mice on a BALB/cJ background,
Rag1!/! mice were on a C57BL/6 background. We generated C5ar1!/!
C3ar1!/! mice by crossing C5ar1!/! and C3ar1!/! mice. All mice were bred
and maintained in specific pathogen-free facilities at the University of Zurich
and University Hospital of Zurich. C57BL/6 / C3!/!, C3!/! / C57BL/6,
C3!/! / C3!/!, and C57BL/6 / C57BL/6 bone-marrow chimeras were
generated as previously described (Probst et al., 2003). All experiments
were performed with age- and sex-matched mice in accordance with the
guidelines of the Swiss federal and cantonal laws on animal protection.
B16F10 melanoma cells (ATCC) and B16F10-OVA (B16F10 stably trans-
fected to express chicken ovalbumin as neo-antigen, provided by Melody
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Swartz, EPFL) were cultured in Dulbecco’s modified Eagle’s medium (DMEM,
GIBCO Invitrogen), CT26 murine colon carcinoma (ATCC) cells in MEM
medium (Invitrogen). Media were supplemented with 10% fetal calf serum,
5 3 10!5 M 2-mercaptoethanol, 10 mM sodium pyruvate 2 mM L-glutamine,
and antibiotics.
In Vivo Experiments
23 105 B16F10-OVA, B16F10 or CT26 were injected s.c. in 100 ml of a 1:1 mix
of PBS and Matrigel Basement Membrane Matrix (BD Biosciences).
Local radiotherapy with a single dose of 20 or 5 Gy was performed at indi-
cated time points using a Xstrahl 200 kV X-ray unit at 1 Gy/min as described
(Gupta et al., 2012). Prior to radiotherapy, mice were anaesthetized by i.p. in-
jection of 50 mg/kg ketamine and 10 mg/kg xylazine.
The C3aR1 antagonist (C3aRA) N2-[(2,2-Diphenylethoxy)acetyl]-L-arginine
(SB290157, Calbiochem) was administered i.p. at 2 mg/kg body weight in
100 ml PBS. Anti-C5aR1 mAb 20/70 (Hycult Biotech) or an isotype control
(rat IgG2b anti-HLA-DR, clone SFRF8B6) was administered i.p. at 0.6 mg/kg
in 100 ml PBS (Baelder et al., 2005; Godau et al., 2004; Sun et al., 2011).
C3aRA and anti-C5aR1 mAb were administered every second day starting
at the day of radiotherapy until the end of the experiment.
To measure the cytokine production in vivo, we injected Brefeldin A (BFA,
Sigma-Aldrich). A 20-mg/ml stock was prepared in DMSO. Further dilution
to 0.5 mg/ml was made in PBS, and 500 ml was injected i.p. 4 hr before
mice were sacrificed (Liu andWhitton, 2005). DEX (Sigma-Aldrich) was admin-
istered daily at 0.3 mg/kg in PBS p.o., starting 1 day before radiotherapy.
Tumors were measured with a caliper every 2–3 days in two dimensions
(length and width). Excised tumors were weighed and processed for flow
cytometry, histology, or isolation of RNA and proteins.
In Vitro Experiments
C57BL/6 and C3!/! mice were bled from the sublingual vein and sera were
collected with Microtainer SST tubes (BD). Sera were diluted 1:10 with PBS,
irradiated with 20 Gy (YXLON Y.SMART582, YXLON International GmbH,
Hamburg, D) and subsequently incubated at 37"C. B16F10-OVA cells were
cultured in 6-well plates (106 cells per well) and irradiated as described above.
Immediately after irradiation, 60 ml of serum from C57BL/6 or C3!/! mice
diluted in 500 ml of PBS was added to the cells. Control samples were not
irradiated but treated similarly otherwise. Supernatants were taken 4 hr and
24 hr after irradiation and were stored at !80"C until further use.
Human Samples
Two sets of biopsies were provided by the Department of Dermatology, Uni-
versity Hospital Zurich. Patients signed informed consent. The ethical commit-
tee of the canton of Zurich approved this study (EK647). (1) Paired biopsies
were collected from two patients with basal cell carcinoma and one with
lentigo maligna melanoma immediately before and 24–36 hr after radiotherapy
(1.5–2 Gy) and were snap frozen. (2) Four biopsies were collected from four
patients (two with basal cell carcinoma, one with melanoma, and one with
squamous cell carcinoma) 24–36 hr after radiotherapy (1.5–2 Gy) but without
previous interventions and were snap frozen.
Statistical Analysis
Results are presented as mean ± SD. Statistical significance was determined
by ANOVA using GraphPad Prism 5 software (GraphPad). When multiple
groups were compared, we used the Bonferroni post-test correction. When
two groups were compared, we used the two-tailed Student’s t test. *, p <
0.05; **, p < 0.01; ***, p < 0.001.
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Figure S1. Radiotherapy results in transient upregulation and activation of 
complement in tumors. Related to Figure 1.  
(A) Radiotherapy-induced changes in immune response-related transcripts. Heatmaps 
of transcripts were created using the log2 value of the fold change of irradiated 
compared to untreated tumors at different time points. (n = 6 mice per time point). 
(B) Comparison of immune response-related transcripts after a single dose of 5 Gy or 
20 Gy. Values represent the fold-increase of irradiated vs untreated samples. Open 
symbols, 5 Gy; closed symbols, 20 Gy. Grey area, no changes in the irradiated sample 
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compared to the untreated one (n = 6 mice per group). 
(C) Radiotherapy activates the classical and alternative pathway of complement. 
C57BL/6 mice were injected s.c. with 2 x 105 B16F10-OVA cells and tumors were 
irradiated 12 d later. Relative expression of Cfb (alternative pathway), C1s (classical 
pathway) and Masp2 (lectine pathway) transcripts at indicated time points after 
radiotherapy. The data shown are the mean ± SD of triplicates from three independent 
analyses.  
(D) Increased phosphorylation of STAT 2, STAT 3 and JAK 4 h after radiotherapy. 
C57BL/6 mice were injected s.c. with 2 x 105 B16F10-OVA cells and tumors were 
irradiated 12 d later. Measurement of STAT 1, STAT 2, STAT 3, NF-kB, JAK and 
their phosphorylated forms by immuno-blot in pooled blood samples from tumor-
bearing and irradiated tumor-bearing mice (4 h after radiotherapy), (n = 3 per group).   
(E) Immunofluorescence staining for C1q (classical pathway), Factor B (alternative 
pathway) and MBL-C (lectine pathway) in irradiated (24 h) and untreated tumors. (n 
= 6 mice per group).  
(F) Quantification of C1q, Factor B and MBL-C by immuno-blot. A representative 
figures from two different experiments is shown.  
The data (C) are shown as the mean ± SD. *P < 0.05, **P < 0.005 by two-way 
analysis of variance (ANOVA) with the Bonferroni correction. 
(G) Radiotherapy-induced complement activation in B16F10 tumors. C56BL/6 mice 
were injected s.c. with 2 x 105 B16F10 cells and tumors were irradiated 13 d later. 
Sections were stained with antibodies recognizing C3b, iC3b and C3c (green), CD31 
for blood vessels (red) and DAPI (blue). Scale bars, 100µm. 
(H) Complement is activated in tumors 24 h after radiotherapy. C57BL/6 mice were 
injected s.c. with 2 x 105 B16F10-OVA cells and tumors were irradiated 12 d later. 
Immuno-blot for C3 cleavage products detected with a polyclonal anti-C3 antibody. 
(D,F,H) Relative band intensities were measured using the Bio-1D software. 
Representative data from three independent experiments are shown. 
(C,D,F,H) Open bars, irradiated (+RT); filled bars, untreated (-RT). 
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Figure S2. C3a and C5a are crucial to the therapeutic efficacy of radiotherapy. 
Related to Figure 2. 
(A,B) C3-/- mice do not respond to radiotherapy. C57BL/6 and C3-/- mice were 
injected s.c. with 2 x 105 B16F10-OVA cells and tumors were irradiated (RT) either 
13 d or 17 d later. (n = 5 mice per group). (A) Tumor weight at endpoint. (B) 
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B16F10-OVA tumors irradiated 17 d after tumor injection. Tumor growth curve and 
weight at endpoint. Representative data from two independent experiments are shown 
as the mean ± SD. **P < 0.005, ***P < 0.0005 by Student’s t test. 
(C) Radiotherapy results in increased expression of C3a, C5a and their receptors in 
the tumor. C57BL/6 mice were injected s.c. with 2 x 105 B16F10-OVA cells and 
tumors were irradiated 12 d later. Detection of C3a and C5a in the untreated and 
irradiated tumors by immuno-blot. 
(D) Detection of C3aR1 and C5aR1 in irradiated (24 h) and untreated tumors 
analyzed by Western blot. Representative data from two independent experiments are 
shown. 
(E) Radiotherapy-induced complement activation in CT26 tumors. BALB/c mice 
were injected s.c. with 2 x 105 CT26 cells and tumors were irradiated 14 d later. 
Sections were stained with antibodies recognizing C3b, iC3b and C3c (green), CD31 
for blood vessels (red) and DAPI (blue). Scale bars, 100µm. 
(F) C3a and C5a are key players in radiotherapy response. BALB/c, C3ar1-/-, C5ar1-/- 
and C3ar1-/-C5ar1-/- mice were injected s.c. with 2 x 105 CT26 cells and tumors were 
irradiated 13 d later. Weight of tumors at endpoint. BALB/c: n = 5 mice per group; 
C3ar1-/-, C5ar1-/- and C3ar1-/-C5ar1-/-: n = 8 mice per group.  
(G) C3a and C5a are key players in radiotherapy response. C57BL/6 mice were 
injected s.c. with 2 x 105 B16F10-OVA cells and tumors were irradiated 12 d later. To 
block the C3aR1, the C3aR1 antagonist SB290157 was administered i.p. at 2 mg/kg 
body weight in 100 µl PBS. To block C5aR1, animals were treated with the 
neutralizing anti-C5aR1 mAb 20/70 or an isotype control i.p. at 0.6 mg/kg in 100 µl 
PBS. C3aRA and anti-C5aR1 mAb were administered every second day starting at the 
day of radiotherapy until the end of the experiment. Weight of tumors at endpoint. n = 
5 mice per group. 
The data are shown as the mean ± SD. *P < 0.05, **P < 0.005 by Student’s t test (A) 
and two-way analysis of variance (ANOVA) with the Bonferroni correction (B). 
(C,D) Relative pixel intensities were calculated using Bio-1D software. 
(A-D,F) Open bars, irradiated (+RT); filled bars, untreated (-RT). 
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Figure S3.  Radiotherapy induces upregulation of transcripts for complement 
and anaphylatoxins receptors by immune cells. Related to Figure 5. 
C57BL/6 mice were injected s.c. with 2 x 105 B16F10-OVA cells and tumors were 
irradiated 12 d later (n = 5 mice per group). 
(A) CD8+ T cells (P7, CD45.2+ TCRβ+ CD8+), CD4+ T cells (P6, CD45.2+ TCRβ+ 
CD4+), DCs (P8, CD45.2+ CD11c+ MHCIIhigh) and the rest of CD45.2+ cells (P9) 
were sorted form untreated and irradiated tumors. Samples were gated on live 
singlets. 
(B) CD45.2+ cells and (C) CD4+ T cells were sorted from untreated and irradiated 
tumors 24 and 168 h after radiotherapy. Complement-related transcripts were 
quantified by qPCR. 
Data are shown as the mean ± SD. *P < 0.05, **P < 0.005, ***P < 0.0005 by two-
way analysis of variance (ANOVA) with the Bonferroni correction. 
 
  
	 64 
  
! 6 
 
 
Figure S4. Radiotherapy fails to promote IFN-γ production in C3ar1-/-C5ar1-/- 
mice; a higher number of FoxP3+ cells in both untreated and irradiated tumors 
in C3ar1-/-C5ar1-/- mice. Related to Figure 6. 
BALB/c and C3ar1-/-C5ar1-/- mice were injected s.c. with 2 x 105 CT26 cells and 
tumors were irradiated 13 d later. Mice were injected with Brefeldin A 4 h before 
euthanasia followed by immediate intracellular staining for IFN-γ.   
(A) Gating strategy for CD8+ T cells.  
(B) Representative example of IFN-γ production by CD8+ T cells in irradiated and 
untreated tumors in BALB/c or C3ar1-/-C5ar1-/- mice.  
(C) Gating strategy for CD4+ T cells.  
(D) Representative example of FoxP3 expression by CD4+ T cells in irradiated and 
untreated tumors in BALB/c or C3ar1-/-C5ar1-/- mice. 
(E,F) C3aR1 and C5aR1 blockade prevents the production of IFN-γ by CD8+ T cells, 
increases the number of Treg, but it does not affect NK cells and B cells numbers. 
C57BL/6 mice were injected s.c. with 2 x 105 B16F10-OVA cells and tumors were 
irradiated (+RT) on d 12. To block the C3aR1, the C3aR antagonist SB290157 was 
administered i.p. at 2 mg/kg body weight in 100 µl PBS. To block C5aR1, animals 
were treated with the neutralizing anti-C5aR1 mAb 20/70 or an isotype control i.p. at 
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0.6 mg/kg in 100 µl PBS. C3aRA and anti-C5aR1 mAb were administered every 
second day starting at the day of radiotherapy until the end of the experiment. (n = 5 
mice per group). (E) Left panel: The total number of infiltrating leukocytes (CD45.2+) 
per gram tumor tissue. Upper right panels: The total number of CD8+ cells (CD45.2+ 
CD8+, left) and of CD8+ cells that produce IFN-γ in vivo (right) per gram tumor tissue. 
Lower right panels: The total number of CD4+ (CD45.2+ CD4+, left) and of FoxP3+ 
CD4+ cells (right) per gram tumor tissue. (F) Left panel: The total number of B cells 
(CD3-NK1.1-CD19+) per gram tumor tissue. Middle panel: The total number of NK 
cells (CD3-NK1.1+) cells per gram tumor tissue. Right panel: The total number of 
CD3-NK1.1+Nkp46+ cells per gram tumor tissue. 
Cells were gated on live singlets, every symbol represents an individual mouse.  
(G-I) Fractionated irradiation causes chronic complement activation and compromises 
CD8+ T cell infiltration.  
(G) C57BL/6 mice were injected with 2x105 B16F10-OVA cells and treated with 
daily fractions of 1.5 Gy or 7 Gy (to reach a cumulative dose of 20 Gy) for 5 
consecutive days starting on d 12. Mice were euthanized on d 13 (24 h after the first 
fraction of radiation), d 17 (24 h after the last fraction of radiation) and d 19 (7 d after 
starting therapy). Fractionated treatments delayed tumor-progression. Growth curves 
of B16F10-OVA tumors (n = 4 mice per group). Untreated (closed black circles), 
irradiated with 1.5 Gy (open circles) and irradiated with 7 Gy (closed grey circles). 
Tumor weight at endpoint (d 19).  
(H) Each irradiation results in complement activation and production of 
anaphylatoxins. Quantification of C3 cleavage products and (D) anaphylatoxins (C3a, 
C5a) by immuno-blot 24 h after the first and the last dose of radiotherapy (1.5 or 7 
Gy). Every dose resulted in complement activation and production of anaphylatoxins. 
Relative band intensities were calculated by using Bio-1D software, (n = 2 mice). 
(I) Fractionated radiotherapy does not result in higher infiltration by leukocytes. The 
total number of leukocytes (CD45.2+ cells of live singlets) per gram tumor tissue. 
Fractionated radiotherapy did not result in higher infiltration by CD8+ T cells. 
Although the number of IFN-γ-producing CD8+ T cells was significantly higher in the 
group treated with 5x 7 Gy when compared to control mice, this was not the case after 
treatment with 5x 1.5 Gy. The total number of CD8+ cells (CD45.2+ CD8+, left panel) 
and of CD8+ cells that produce IFN-γ in vivo (right panel) per gram tumor tissue. 
Mice were injected i.p. with Brefeldin A 4 h before euthanasia followed by immediate 
intracellular staining for IFN-γ. Fractionated radiotherapy did not result in higher 
infiltration by CD8+ T cells. Although the number of IFN-γ-producing CD8+ T cells 
was significantly higher in the group treated with 5x 7 Gy when compared to control 
mice, this was not the case after treatment with 5x 1.5 Gy. Every symbol represents 
an individual mouse.  
Data are shown as the mean ± SD. *P < 0.05, **P < 0.005, ***P < 0.0005 by two-
way analysis of variance (ANOVA) with the Bonferroni correction.  
+RT, irradiated; -RT, untreated. !  
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SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
 
Quantitative real-time PCR (qPCR) 
Tumors were harvested 4, 24, 96 and 168 h after radiotherapy. For each time point, 
untreated tumors were used as control. Excised B16F10-OVA tumors were collected 
in 1 mL Trizol Reagent (Life Technologies) per 0.2 g of tissue. Samples were 
homogenized with the FastPrep24 homogenizer (MpBio) for 2 cycles of 30¨ 
according to the manufacturer’s instructions and RNA was isolated according to the 
Trizol protocol. The extracted RNAs from three tumors of the same experimental 
group were pooled. The concentration and the purity of the extracted RNA were 
assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies). Only samples 
with a RIN (RNA integrity number) > 3 were used for subsequent qPCR. RNA was 
reverse transcribed using the High Capacity cDNA Reverse Transcription Kit (Life 
Technologies) according to the manufacturer’s instructions. qPCR was performed 
using commercially available TaqMan primers (Applied Biosystems). Reactions were 
run on the RotoGene Cycler (Corbett Research). Results were normalized to Gadph 
and displayed as relative expression. 
 
TaqMan mouse immune response array  
Samples were processed and RNA was extracted and reverse transcribed as described 
above and only samples with a RIN > 5 were used. cDNA was used to run the 
TaqMan Array 96-well Mouse Immune Response Plate in a AB 7900HT (Applied 
Biosystems) machine according to the manufacturer’s instructions. Data were 
collected as CT values and log2 of the fold change values comparing tumors with and 
without radiotherapy were calculated. These values were normalized against the four 
different endogenous controls present in the panel meaning (Gadph, Hprt1, Gusb and 
18S).  Data were processed using R/Bioconductor(Gentleman et al., 2004). The 
heatmap was generated with the heatmap.2 function from the package gplots and 
represents the clustering of samples using the Pearson’s correlation as a distance 
measure and “complete” linkage function. Genes for the plot of the time series have 
been selected by a formula choosing shape of the profile in the dataset where log2 fold 
changes in the time point behave as follows: FCt1>0 FCt2>0 and FCt4<0. The 
selected genes are coloured according to the log2 fold change values at t2 from 
highest (red) to lowest (blue). 
 
Western blotting 
Tumors were collected in PBS containing a cocktail of protease inhibitors 
(SIGMAFAST protease inhibitor, Sigma-Aldrich) prepared as indicated by the 
provider. Serum was collected with Microtainer SST tubes (BD) at the indicated time 
points to check for systemic complement activation. Tumors were homogenized with 
the FastPrep24 homogenizer as described above. The protein concentration in 
homogenized tumor samples was determined using a NanoDrop ND-1000 
Spectrophotometer or by a Bradford assay (Promega). Western blots were performed 
as described (Lin et al., 2001) using 12% polyacrylamide gels. Blots were evaluated 
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using a Fusion-FX7 SPECTRA machine and Bio1D software (VILBER LOURMAT, 
Eberhardzell, Germany). Results are expressed as relative pixel intensity, which was 
calculated as follows: pixels of the protein of interest divided by the pixels of the 
internal standard of the same sample (β-actin for tissues, transferrin or IgG for 
serum). 
 
Immunofluorescence 
Tumors were collected in OCT (Tissue-Tek Optimal Cutting Temperature 
Compound, Sakura), gently frozen in liquid nitrogen and stored at -80ºC for 24 h. 
Samples were then left for 30’ at -20ºC and processed into 7-µm thick sections using 
a microtome at -20ºC. Cryoections were blocked for 1 h at room temperature in a 
blocking solution (PBS containing 10% FCS and 0.1% TritonX), washed with PBS 
and incubated overnight at 4ºC with primary antibodies diluted in blocking solution. 
Sections were washed with PBS and incubated with secondary antibodies diluted in 
blocking solution for 1 h at room temperature. After a final wash with PBS, slides 
were mounted in Mowiol anti-fade solution (Sigma-Aldrich). Sections were 
photographed using a Leica DMI6000 inverted microscope (Leica microsystem, 
Wetzlar, Germany). Sections were evaluated using ImageJ software. 
 
Quantitative and qualitative analysis of complement activation 
To quantitatively and qualitatively analyze the presence of proteins of the 
complement system in the tumor mass, we performed Western blot analyses and 
immunofluorescence. 
For Western blot analysis, tumors were collected in PBS containing a cocktail of 
protease inhibitors (SIGMAFAST protease inhibitor, Sigma-Aldrich) prepared as 
indicated by the provider. Serum was collected with Microtainer SST tubes (BD) at 
the indicated time points to check for systemic complement activation. Tumors were 
homogenized with the FastPrep24 homogenizer as described above. The protein 
concentration in homogenized tumor samples was determined using a NanoDrop ND-
1000 Spectrophotometer or by a Bradford assay (Promega). Western blots were 
performed as described (Lin et al., 2001) using 12% polyacrylamide gels. Blots were 
evaluated using a Fusion-FX7 SPECTRA machine and Bio1D software (VILBER 
LOURMAT, Eberhardzell, Germany).  
For immunofluorescence, tumors were collected in OCT (Tissue-Tek Optimal Cutting 
Temperature Compound, Sakura), gently frozen in liquid nitrogen and stored at -80ºC 
for 24 h. Samples were then left for 30’ at -20ºC and processed into 7-µm thick 
sections using a microtome at -20ºC. Cryoections were blocked for 1 h at room 
temperature in a blocking solution (PBS containing 10% FCS and 0.1% TritonX), 
washed with PBS and incubated overnight at 4ºC with primary antibodies diluted in 
blocking solution. Sections were washed with PBS and incubated with secondary 
antibodies diluted in blocking solution for 1 h at room temperature. After a final wash 
with PBS, slides were mounted in Mowiol anti-fade solution (Sigma-Aldrich). 
Sections were photographed using a Leica DMI6000 inverted microscope (Leica 
microsystem, Wetzlar, Germany). Sections were evaluated using ImageJ software. 
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Activated complement was detected using rat anti-mouse C3b/iC3b/C3c mAb (clone 
2/11, Hycult Biotech) that specifically recognizes C3 cleavage products but not 
inactive C3(Mastellos et al., 2004). Furthermore, we used rat anti-mouse C1q mAb 
(Abcam), goat anti-mouse MBL (Santa Cruz Biotechnology), rabbit anti-mouse 
Factor B (Thermo Fisher Scientific), polyclonal rabbit anti-mouse C3 (Hycult 
Biotech), rat anti-mouse C3a (clone 3/11 Hycult Biotech) and rat anti-mouse C5a 
(R&D Systems), rabbit anti-C5aR (Proteintech Group), mouse anti-C3aR (clone D12, 
Santa Cruz Biotechnology) and Alexa Fluor 647 anti-mouse CD31 (Biolegend, red 
fluorescence). As a loading control, we used monoclonal mouse anti-β-actin (AC-15, 
Sigma Aldrich) or HRP-labeled goat anti-mouse IgG (Fc fragment, Jackson 
ImmunoResearch) in the case of serum. In case of Western blots, primary antibodies 
were detected with HRP-labeled goat anti-rat (Sigma-Aldrich), HRP goat anti-rabbit 
(Abcam), HRP-labeled donkey anti-goat (Abcam). In case of immunofluorescence, 
we used Cy2-labelled donkey anti-rat or rat anti-mouse antibodies (The Jackson 
Laboratory) (green) to detect primary antibodies. DAPI (Sigma-Aldrich) was used to 
stain nuclei (blue). 
 
Antibodies for Western blotting and immunofluorescence 
Activated complement was detected using rat monoclonal anti-mouse C3b/iC3b/C3c 
mAb (clone 2/11, Hycult Biotech) that specifically recognizes C3 cleavage products 
but not inactive C3 (Mastellos et al., 2004). Furthermore, we used monoclonal rat 
anti-mouse C1q (clone JL-1 Hycult Biotech), polyclonal goat anti-mouse MBL-C 
(Santa Cruz Biotechnology), polyclonal rabbit anti-mouse Factor B (Thermo Fisher 
Scientific), polyclonal rabbit anti-mouse C3 (Hycult Biotech), monoclonal rat anti-
mouse C3a mAb (clone 3/11 Hycult Biotech) and monoclonal rat anti-mouse C5a 
mAb (clone 295103 R&D Systems), polyclonal rabbit anti-C5aR (Proteintech Group), 
polyclonal mouse anti-C3aR (Santa Cruz Biotechnology) and Alexa Fluor 647 anti-
mouse CD31 (Biolegend, red fluorescence).  
The proteins that belong to the JAK/STAT and NFkB pathways and their 
phosphorylated forms were analyzed using polyclonal rabbit anti-mouse Stat-1 (Cell 
Signaling), polyclonal rabbit anti-mouse P-Stat-1 (pY701) (Cell Signaling), 
polyclonal rabbit anti-mouse Stat-2 (Upstate), rabbit anti-mouse P-Stat-2 (pY690) 
(Santa Cruz Biotech), monoclonal rabbit anti-mouse Stat-3 (D3Z2G Cell Signaling), 
polyclonal rabbit anti-mouse P-Stat-3 (pY705) (Cell Signaling), polyclonal rabbit 
anti-mouse Jak1 (Santa Cruz Biotech), polyclonal rabbit anti-mouse P-Jak1 
(pY1022/1023) (Cell Signaling), monoclonal mouse anti-mouse IκBα (clone 112B2 
Cell Signaling) and monoclonal mouse anti-mouse P-IκBα (5A5 Cell Signaling). 
As a loading control, we used monoclonal mouse anti-β-actin (AC-15, Sigma 
Aldrich) or HRP-labeled goat anti-mouse IgG (Fc fragment, Jackson 
ImmunoResearch) and polyclonal rabbit anti-mouse transferrin (Thermo Scientific) in 
the case of serum. In case of Western blots, primary antibodies were detected with 
HRP-labeled goat anti-rat (Sigma-Aldrich), HRP goat anti-rabbit (Abcam), HRP-
labeled donkey anti-goat (Abcam). Cy2-labelled donkey anti-rat or rat anti-mouse 
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antibodies (The Jackson Laboratory) (green) were used to detect primary antibodies. 
DAPI (Sigma-Aldrich) was used to stain nuclei (blue).  
 
Electron Microscopy (EM) 
For EM, tissue samples at different time points from two spots of two mice were fixed 
in Karnovsky’s fixative. Postfixation was done with 1% Osmiumtetroxide in 0,1 M 
cacodylatebuffer, after washing tissues were stained en bloc with Ultrastain 1 (Leica, 
Vienna, Austria) followed by ethanol dehydration series. Finally the samples were 
embedded in a mixture of DDSA/NMA/Embed-812 (EMS, Hatfield, U.S.A), 
sectioned and stained with Ultrastain 2 (Leica, Vienna, Austria) and analyzed with a 
CM10 electron microscope (FEI, Eindhoven, the Netherlands). 
 
Sample preparation for flowcytometry and sorting 
Tumors were harvested and cut in small pieces followed by digestion using 1.5 
mg/mL Collagenase IV (Roche) plus 100 µg/mL DNase I (Sigma-Aldrich) in media 
for 1 h at 37ºC. Samples were filtered through a 0.45 µm cell strainer, centrifuged and 
resuspended in FACS buffer (PBS containing 2% FCS, 0,05% NaN3, 20 mM EDTA) 
or PBS, depending on the staining panels. Cells were stained with antibodies to the 
following markers: CD45.2 (Clone: 104, Biolegend), MHCII (Clone: M5/114.15.2, 
Biolegend), CD70 (Clone: FR70, eBioscience), CD86 (Clone: GL-1, Biolegend), 
CD11c (Clone: N418, eBioscience), CD4 (Clone: RM4-5, Biolegend), CD8β (Clone: 
53-5.8, Biolegend) (Clone: YTS156.7.7, Biolegend), TCRβ (Clone: H57-597, BD 
Biosciences), IFNγ (Clone: XMG1.2, Biolegend), FoxP3 (Clone: FJK-16s, 
eBioscience), LIVE⁄DEAD Fixable Aqua Dead Cell Stain Kit (Molecular Probes, 
Invitrogen), LIVE/DEAD Fixable Violet Dead Cell Stain Kit (Molecular Probes, 
Invitrogen). Samples were measured using a CyAn ADP9 analyzer (Beckman 
Coulter), sorting was performed using a FACS Aria II (BD Bioscience). Data were 
analyzed using FlowJo software (Tree Star Inc.). 
 
Human Samples  
Samples were transferred in Trizol reagent and processed according to the 
manufacturer’s instructions for RNA (for qPCR) and protein (for Western blot) 
isolation. Briefly, after homogenizing the sample with the FastPrep24 homogenizer 
we added chloroform to separate the homogenate into a clear upper aqueous layer 
(containing RNA), and a red lower layer (containing the DNA and proteins). RNA 
was precipitated from the aqueous layer with isopropanol. DNA was precipitated with 
ethanol and proteins were precipitated from the phenol-ethanol supernatant by 
isopropanol. The precipitated RNA or proteins were washed with ethanol to remove 
impurities, and then dissolved in RNase-free water or 300 µL of water with 1% SDS, 
respectively. As only RNA samples with a RIN > 3 were used for qPCR, we excluded 
one sample (RIN = 2.10) from further analysis. qPCR was performed using 
commercially available TaqMan primers (Applied Biosystems). Results were 
normalized to Gadph and displayed as relative expression. 
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Isolated proteins were quantified using a Nanodrop ND-1000 spectrophotometer and 
loaded on 12% polyacrylamide gels. We used anti-human C3 antibody (Thermo 
Scientific) and monoclonal human anti-β-actin (Sigma-Aldrich). Blots were evaluated 
using a Fusion-FX7 SPECTRA machine and Bio1D software (VILBER LOURMAT, 
Eberhardzell, Germany). 
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Introduction and Aims 
 
The lymphatic system is a network of vessels that is generated during embryogenesis after blood 
vasculature is formed. Differentiated lymphatic endothelial cells (LECs) exit blood vessels and 
form the lymphatic sacs, an initial structure from which lymphatic vessels of peripheral organs 
develop (Stanczuk et al., 2015). Lymphatic capillaries in tissues are blind-ended structures that are 
composed of a continuous layer of loose LECs surrounded by elastic fiber. In contrast to blood 
vessels, lymph vessels do not contain pericytes. This conformation renders lymphatic vessels 
highly permeable to large macromolecules, pathogens and migrating cells (Figure 1).  
 
                             
Figure 1. Structural organization of the lymphatic system. a) Lymphatic vessel subtypes. The structure of 
the LECs in the initial lymphatics is shown in details in the two pull-out boxes (Stacker et al., 2014).  
 
Interstitial fluid (also called lymph) enters the lymphatic vessels from the extracellular space within 
tissues and is transported through skeletal muscle contraction and respiratory movement. During 
this process, lymph is transported through the lymph nodes, is collected by larger collecting vessels 
finally reaching the thoracic duct from where it reaches the blood (Alitalo, 2011). 
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The lymphatic system transports the protein-rich interstitial fluid back to the bloodstream and 
facilitates the absorption of dietary fat. Besides this, the lymphatic system is a crucial component of 
the immune system and includes secondary lymphatic organs such as lymph nodes, tonsils, Peyer's 
patches and spleen. LECs regulate the trafficking of leukocytes to and from the lymph node (LN) 
(Pham et al., 2010). Small and large antigens collected from tissues reach the draining lymph node 
(DLN) through the afferent lymphatic vessels and can be taken up by antigen presenting cells 
(APCs). In particular, dendritic cells are specialized APCs that have a dual role in inducing 
adaptive immune response to foreign antigens in the presence of costimulatory signals (priming) 
and in maintaining T cell tolerance to self (Steinman and Banchereau, 2007).  
Inflammation is associated with remodeling of blood and lymphatic vessels (Halin and Detmar, 
2008). For example, solid tumors structurally and functionally modulate the lymphatic system 
through the production of VEGF-C. The VEGFC-VEGFR3 axis is considered the most important 
driving factor for tumor-associated lymphangiogenesis (Tammela and Alitalo, 2010). Although 
lymphatic vessels were originally thought to be a passive feature in antigen transportation and 
metastatic tumor spread, recent evidence demonstrated that LECs are active players in both 
processes. It was shown that LECs take up tumor antigens and present them on MHC-I molecules 
to CD8+ T cells. This resulted in T cell tolerance due to the lack of co-stimulatory molecules and 
the expression of PD-L1 on the surface of LECs (Lund et al., 2012). Many tumors have been 
reported to disseminate first through the lymphatic system. In human malignant melanoma, 
increased lymphatic density in the periphery correlated with metastasis (Shields et al., 2004). 
Tumor associated draining lymph nodes but not naïve lymph nodes are lymphangiogenic and with 
an immunosuppressive environment (Shields et al., 2010). They are shaped by the tumor in order to 
be an “escape route” for metastatic cells (Preynat-Seauve et al., 2007; Stacker et al., 2014). 
Radiotherapy, a widely used treatment for cancer patients, has been reported to impact on the 
number of tumor-associated lymphatic vessels (Avraham et al., 2010). In addition, antigen 
presentation in the draining lymph node was improved by local irradiation of the tumor and 
correlated with an increased number of tumor-infiltrating CD45.2+ cells (Lugade et al., 2005). 
However, the impact of local radiation on the structure and functionality of lymphatic vessels is 
still unknown. We therefore investigated the effect of radiotherapy on tumor-associated lymphatic 
vessels. 
 
Results 
 
Overexpression of VEGF-C causes lymphangiogenesis and tumor progression (Skobe et al., 2001). 
To analyze whether the amount of lymph vessels has an effect on the efficacy of radiotherapy, we 
injected C57BL/6 mice s.c. with B16F10-OVA (B16-OVA) and B16F10-OVA-VEGFC (B16-
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OVA-VC) cells. VEGF-C-expressing tumors contained an increased amount of peritumoral and 
intratumoral lymphatic vessels (data not shown). B16-OVA-VC grew significantly faster than B16-
OVA, in agreement with earlier data (Skobe et al., 2001). Nevertheless, tumors responded equally 
well to radiotherapy applied as a single dose of 20 Gy (Figure 1A), suggesting that the number of 
tumor-associated lymph vessels does not influence susceptibility to radiotherapy.  We quantified 
Vegfc, Kdr (VEGF receptor 2) and Flt4 (VEGF receptor 3) by quantitative real-time PCR (qPCR) 
in the tumors at the end point of the experiment. As expected, the amount of Vegfc transcripts was 
elevated in B16-OVA-VC compared to B16-OVA tumors, and radiotherapy did not change this 
(Figure 1B, left panel). The amount of Kdr and Flt4 were similar in both tumors and did not 
change upon radiotherapy (Figure 1B, middle and right panels). 
 
 
Figure 1. Radiotherapy efficacy is not dependent on the amount of lymphatic vessels. C57BL/6 mice 
were injected s.c. with 2 x 105 B16F-OVA-VC or B16F-OVA cells and were irradiated with a single dose of 
20 Gy on d 12, or left untreated. A) Tumor growth curves. Data are shown as mean ± SD. *p < 0.05 ***p < 
0.0005 by two-way analysis of variance (ANOVA) with the Bonferroni correction B) Relative expression of 
Vegf-c, Kdr, Flt4 transcripts in the tumor at end point. (n = 5 mice per group). 
 
To analyze the immediate effect of different doses of radiotherapy on tumor-associated lymphatic 
vessels we injected B16-OVA-VC cells, irradiated established tumors with a single dose of 5 or 20 
Gy and analyzed the amount of Vegfc transcripts by qPCR and the density of lymphatic vessels by 
immunofluorescence in the tumor 24 h later. Neither Vegfc transcripts (Figure 2A) nor the density 
of lymphatic vessels (Figure 2B) changed after radiotherapy, suggesting that lymphatic vessels are 
relatively radio-insensitive.  
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Figure 2. Lymphatic vessels are not radiosensitive. C57BL/6 mice were injected s.c. with 2 x 105 B16-
OVA-VC cells and were irradiated with a single dose of 20 or 5 Gy on d 12, or left untreated. Tumors were 
harvested 24 h after the treatment. A) Relative expression of Vegfc transcripts. B) Immunofluorescence 
untreated and irradiated tumors. Sections were stained with DAPI (left column); Lyve-1 antibody for 
lymphatic vessels (green fluorescence, middle column) and merged image of Lyve-1 and CD31 antibody for 
blood vessels (red fluorescence, right column). (n = 5 mice per group) 
 
Tumors drive lymphangiogenesis, which occurs intratumorally, peritumorally and in the DLN. 
Whereas lymphatic vessels in the tumor are collapsed and not functional, peritumoral vessels are 
functional and associated with metastasis (Padera et al., 2002). We measured the function of 
lymphatic vessels function by injecting rhodamine dextran into B16-OVA tumors as described 
(Lund et al., 2012) or by intravital microscopy (Proulx et al., 2010). We used B16-OVA cell line 
instead of B16-OVA-VC to have a more physiological model. B16-OVA-VC tumors have an 
enormous amount of lymphatic vessels compared to B16-OVA ones (Lund et al., 2012). Using two 
independent methods, we observed that the function of tumor-associated lymphatic vessels was 
increased in irradiated compared to untreated tumors (Figure 3A and 3B), but additional analyses 
must be performed to further clarify impact of radiotherapy on tumor-associated lymphatic vessels. 
We could conclude that radiotherapy does not affect the structure of tumor-associated lymphatics 
but only the function. 
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Figure 3. Radiotherapy results in increased function of tumor-associated lymphatic vessels. A) 
C57BL/6 mice were injected s.c. with 2 x 105 B16-OVA cells and received a single dose of 20 Gy on d 12, or 
were left untreated. Rhodamine dextran was injected intratumorally 30 minutes before harvesting tumors and 
draining lymph nodes at the indicated time points. (n = 5 mice per group) B) Two x 105 B16-OVA cells in 50 
µl PBS were injected in the footpad of C57BL/6 mice. Twelve days later, footpads were irradiated with a 
single dose of 20 Gy on d 12, or left untreated. LP-ICG (liposomal formulation of indocyanine green) was 
intradermally injected at the border of the tumor and images were acquired at the indicated time points.  (n = 
2 mice per group) 
 
It was shown that cross-presentation by tumor infiltrating DCs increases upon radiotherapy in a 
type-I-IFN dependent manner (Burnette et al., 2011), but data on cross-presentation in the tumor-
draining lymph nodes are not available. Since our preliminary data show that radiotherapy results 
in increased lymphatic flow, we investigated whether radiotherapy influences the amount of cross-
presented tumor antigens in the draining lymph node. Therefore, we injected C57BL/6 mice with 
B16-OVA or B16-OVA-VC cells and irradiated tumors 12 d later with 20 Gy or left them 
untreated. Two days after radiotherapy, DLN were harvested, pooled per experimental group and 
stained for sorting. Sorting was performed according to the gating strategy in Figure 4. We isolated 
CD8α+ DC (P7, CD45.2+ CD11c+ MHCIIhigh CD8α+), CD8α- DC (P6, CD45.2+ CD11c+ MHCIIhigh 
CD8α-) and a negative fraction (P5, CD45.2+ CD11c- MHCII- CD8α-).  
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Figure 4. Sorting of dendritic cells from DLN of untreated and irradiated tumors. C57BL/6 mice were 
injected s.c. with 2 x 105 B16-OVA-VC or B16-OVA cells and received a single dose of 20 Gy 12 d later. 
Draining lymph nodes were harvested 2 days later and pooled for sorting analysis. The plot on the left shows 
P5 population (red) CD11c- MHCII- (gated on CD45.2+ live singlets). The plot on the right shows P6 (black) 
CD8α+ CD11c+ MHCIIhigh and P7 (green) CD8α- CD11c+ MHCIIhigh (both previously gated on P4). 
 
We repeated the experiment in order to reach the required amount of cells (≈ 107) for the proteomic 
analysis (LC-MS-MS) performed by Prof. Anthony Purcell (Monash University, Melbourne) as 
previously reported (Gerlach et al., 2011). The total amount of cells collected from the different 
sorting for the three populations is reported in the table (Table 1). We did not find any difference 
in the amount of cells recovered from untreated and irradiated tumors.  
 
 
B16-OVA 
-RT 
B16-OVA 
+RT 
neg 
fraction 2.06 x 107 3.4 x 107 
CD8α-DC 2.18 x 105 2.57 x 105 
CD8α+DC 8.64 x 104 8.57 x 104 
 
B16-OVA-VC -
RT 
B16-OVA-VC 
+RT 
neg 
fraction 3.53 x 107 3.03 x 107 
CD8α-DC 2.01 x 105 1.89 x 105 
CD8α+DC 1.08 x 104 9.19 x 104 
 
Table 1. Total amount of cells for the different sorted populations. The total number of cells for the 
different populations from DLN of mice injected with B16-OVA and B16-OVA-VC irradiated or not (+/- 
RT) are listed in the second and third columns. Negative fraction (neg) indicates CD11c- MHCII- cells (gated 
on CD45.2+ live singlets), CD8α+DC indicates (CD8α+ CD11c+ MHCIIhigh) and CD8α-DC (CD8α- CD11c+ 
MHCIIhigh). 
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We aimed to quantify the amount of ovalbumin-derived SIINFEKL peptide presented by H-2Kb by 
mass spectrometry (Croft et al., 2013), however, the amount of SIINFEKL was under the detection 
limit in all samples (data not shown). To better address the question additional experiments are 
needed including a kinetic analysis of the samples described above.  
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Discussion 
 
Lymphatic vessels have been reported to have a controversial role in cancer development. They are 
fundamental to develop a tumor-specific immune response because they transport tumor antigens 
and dendritic cells to secondary lymphoid organs where T cells are primed. On the other hand it 
has been proven that LECs and factors released by the tumor, can render T cells ineffective by 
creating a suppressive environment (Munn and Mellor, 2006). Moreover, lymphatic vessels 
together with blood vessels are the only possible route for tumor cells to metastasize; in fact 
regional lymph nodes are the first sites of metastasis in many cancers. Metastases in the lymph 
node are considered a negative prognostic factor for cancer patients (Sleeman and Thiele, 2009) 
and are used in the clinics to define the stage of the tumor (Leong et al., 2006). Nevertheless 
extensive studies on tumor-associated lymphatic vessels have been performed; their role in the 
development of tumor-specific immunity, tumor growth and the formation of metastases is still 
unclear.   
Radiotherapy modulates the tumor microenvironment and promotes inflammation (Thompson and 
Maity, 2014). We embarked to investigate whether radiotherapy impacts on the structure and/or the 
function of tumor-associated lymphatic vessels. Since VEGF-C is the factor driving 
lymphangiogenesis and it has also been correlated with increased formation of metastases (Pepper 
et al., 2000), we therefore analyzed the amount of VEGF-C transcripts upon radiotherapy. We 
could not find any difference in expression levels comparing irradiated tumors to untreated ones. 
At the functional level, we could show an enhanced drainage upon radiotherapy but no changes in 
the structure of tumor-associated lymphatic vessels. One possible explanation for our observations 
could be that the increase in drainage is a direct consequence of the radiotherapy-mediated 
inflammation. In fact, it has been published that inflammatory processes cause expansion of the 
lymphatic network and increase in the drainage (Kim et al., 2012). Changes in the function of 
tumor-associated lymphatic vessels, as an increase in the drainage, might have consequences on the 
type of immune response developed in the DLN. As previously reported for other models, 
continuous exposure to the antigen can lead to the promotion of tolerance (Vignali et al., 2008). 
Characterizing the dynamics of antigen transportation to the DLN upon radiotherapy could be 
interesting to better understand the development of radiotherapy-mediated tumor-specific 
immunity. For example, recent studies have highlighted a new role of lymphatic endothelial cells 
on T-cell fate and function. It has been shown that LECs, that lack co-stimulatory molecules and 
express PD-L1 (Tewalt et al., 2012), can actively scavenge antigens and present them on MHC 
class I molecules driving immune tolerance (Lund et al., 2012). LECs can also directly dampen DC 
maturation (Podgrabinska et al., 2009). It would be interesting to repeat the analysis of changes in 
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the antigen load by mass spectrometry in the DLN upon radiotherapy and couple it with an 
extensive study of the DLN environment and immune response. 
In conclusion, it could be highly relevant to better characterize lymphatic vessel modification upon 
irradiation in order to clarify if the can be exploited improve the current status of the therapy. 
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Material and Methods 
 
Cell lines and mice 
C57BL/6 (C57BL/6JOlaHsd) mice were purchased from the Harlan (Rijswijk, The Netherlands). 
All experiments were performed with age- and sex-matched mice in accordance with the guidelines 
of the Swiss federal and cantonal laws on animal protection. 
B16-OVA (B16F10 stably transfected to express chicken ovalbumin as neo-antigen) and B16-
OVA-VEGF-C (B16-OVA stably transfected to express VEGF-C) were provided by Melody 
Swartz, EPFL, Lausanne, Switzerland). Cell lines were cultured in Dulbecco's modified Eagle's 
medium (DMEM, GIBCO Invitrogen) supplemented with 10% fetal calf serum, 5 x 10-5 M 2-
mercaptoethanol, 10 mM sodium pyruvate 2 mM L-glutamine and antibiotics. 
 
In vivo experiments 
Two x 105 tumor cells were injected s.c. on the left or right flank of mice in 100 µl of a 1:1 mix of 
PBS and Matrigel™ Basement Membrane Matrix (BD Biosciences). For footpad injection 2 x 105 
cells were injected in a volume of 50 µl of PBS. 
Local radiotherapy with a single dose of 20 or 5 Gy was performed at indicated time points using a 
Xstrahl 200 kV X-ray unit at 1 Gy/min as described (Gupta et al., 2012). Prior to radiotherapy, 
mice were anaesthetized by i.p. injection of 50 mg/kg ketamine and 10 mg/kg xylazine. Tumors 
were measured with a caliper every 2-3 days in two dimensions (length and width).  
 
Quantitative real-time PCR (qPCR) 
Excised tumors were collected at the indicated time points in 1 ml Trizol Reagent (Life 
Technologies) per 0.2 g of tissue. Samples were homogenized with the FastPrep24 homogenizer 
(MP Bio, France) for 2 cycles of 30 seconds according to the manufacturer’s instructions and RNA 
was isolated according to the Trizol protocol. The concentration and the purity of the extracted 
RNA were assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies). Only samples 
with a RIN (RNA integrity number) > 3 were used for subsequent qPCR. RNA was reverse 
transcribed using the High Capacity cDNA Reverse Transcription Kit (Life Technologies) 
according to the manufacturer’s instructions. qPCR was performed using commercially available 
TaqMan primers for Vegfc, Kdr and Flt4 (Applied Biosystems). Reactions were run on the 
RotorGene Cycler (Qiagen). Results were normalized to Gadph and displayed as relative 
expression. 
 
Immunofluorescence 
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Irradiated and untreated tumors were collected in OCT at the indicated time points (Tissue-Tek 
Optimal Cutting Temperature Compound, Sakura), gently frozen in liquid nitrogen and stored at -
80ºC for 24 h. Samples were then left for 30’ at -20ºC and processed into 7-µm thick sections using 
a microtome at -20ºC. Cryoections were blocked for 1 h at room temperature in a blocking solution 
(PBS containing 10% FCS and 0.1% TritonX), washed with PBS and incubated overnight at 4ºC 
with primary antibodies diluted in blocking solution. Sections were washed with PBS and 
incubated with secondary antibodies diluted in blocking solution for 1 h at room temperature. 
Slides were mounted in Mowiol anti-fade solution (Sigma-Aldrich). Sections were photographed 
using a Leica DMI6000 inverted microscope (Leica microsystem, Wetzlar, Germany). Sections 
were evaluated using ImageJ software. 
Blood vessels were detected using Alexa Fluor 647 anti-mouse CD31 antibody (Biolegend, red 
fluorescence), lymphatic vessels were detected using rabbit polyclonal anti-mouse Lyve-1 
antibody; DAPI (Sigma-Aldrich) was used to stain nuclei. Cy2-labelled donkey anti-rabbit (The 
Jackson Laboratory) (green) were used to detect rabbit-anti-mouse Lyve-1 primary antibody. 
 
Function of lymphatic vessels 
Twenty µl of rhodamine dextran were injected into untreated and irradiated tumors on one flank of 
mice. After 30 minutes, tumors and tumor draining lymph nodes were harvested. LNs were 
homogenized and fluorescence was quantified by plate reader. 
For the live imaging of lymphatic vessels function, mice were anesthetized with 2% isofluorane 
and placed inside IVIS Spectrum (Xenogen, Caliper Life Sciences). The imaging parameters were 
set as reported in (Proulx et al., 2010). Five µl of the liposomal (LP) ICG (15 µmol/L) was injected 
at the border of the primary tumor in the footpad and images were acquired at the indicated time 
points. The liposomal formulation of indocyanine green (LP-ICG) is described to be specifically 
taken up by lymphatic vessels (Proulx et al., 2010). For image analysis, Living Image Software 
(Caliper Life Sciences) was used. For assessments of flow through the inguinal lymph node, the 
data were analyzed as described before (Proulx et al., 2010).  
 
Sorting of tumor-associated dendritic cells 
Tumors were harvested and cut in small pieces followed by digestion using 1.5 mg/mL 
Collagenase IV (Roche) plus 100 µg/mL DNase I (Sigma-Aldrich) in media for 1 h at 37ºC. 
Samples were filtered through a 0.45 µm cell strainer, centrifuged and resuspended in PBS. Cells 
were stained with antibodies to the following markers: CD45.2 (Clone: 104, Biolegend), MHCII 
(Clone: M5/114.15.2, Biolegend), CD11c (Clone: N418, eBioscience), CD8α (Clone: 53-6.7 
Biolegend), LIVE⁄DEAD Fixable Aqua Dead Cell Stain Kit (Molecular Probes, Invitrogen). 
	 82 
Samples were sorted using a FACS Aria II (BD Bioscience). Data were analyzed using FlowJo 
software (Tree Star Inc.). 
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Discussion 
 
 
Calor (heat), dolor (pain), tumor (swelling) and rubor (redness) are the cardinal signs of 
inflammation identified by the Roman encyclopaedist Aulus Cornelius Celsus in AD 30. 
Inflammation is a physiological response to perturbation such as infection or tissue damage that 
aims to restore the steady state as soon as possible. Because inflammation is a potent and in 
principle destructive response, it is tightly regulated and such controlled inflammatory response is 
beneficial to the host. In contrast, chronic inflammation seems uncoupled from the initial event 
including infection or tissue repair and is associated with an imbalance of physiological responses. 
Chronic inflammation is detrimental and causes a wide array of pathologies such as rheumatoid 
arthritis, inflammatory bowel disease, atherosclerosis, type 2 diabetes, Alzheimer’s disease, 
cardiovascular disease, multiple sclerosis and cancer 	 (Balkwill and Mantovani, 2001; Medzhitov, 
2008). 
Acute inflammation is triggered by infection or injury and results in coordinated recruitment of 
leukocytes to the affected site. The response to pathogens is better characterized than that to injury 
and starts with the recognition of the microbe by tissue-resident macrophages and mast cells, 
resulting in local production of pro-inflammatory mediators including vasoactive amines and 
peptides, lipids, enzymes, chemokines, cytokines and fragments of complement components such 
as anaphylatoxins (C3a, C5a) (Medzhitov, 2008). Upon elimination of the infectious agent, 
inflammation resolves and tissue repair is initiated (Serhan and Savill, 2005).  
Failure to clear the pathogen or restore homeostasis results in chronic inflammation with changed 
characteristics to avoid collateral damage to the host. For example, the infiltrate contains more 
macrophages and lymphocytes than neutrophils, tertiary lymphoid structures may be formed and 
anti-inflammatory and immunosuppressive factors such as IL-10 are produced. In addition, 
processes associated with tissue repair and destruction occur simultaneously (Drayton et al., 2006; 
Medzhitov, 2008). 
Already in the 19th century, Rudolf Virchow observed infiltrating leukocytes in the tumor and 
suggested a possible link between inflammation and cancer (Virchow, 1881). Nowadays 
inflammation is considered a hallmark of cancer (Hanahan and Weinberg, 2011). Apparently at 
odds with this theory, Coley and Fehleisen independently observed that erysipelas – a severe 
infection of the skin with Streptococcus pyogenes – resulted in cure of some cancer patients and 
suggested that inflammation leads to tumor regression (Coley, 1891; Modlin, 2012). 
This apparent paradox can be explained by the nature of the inflammatory response: Acute 
inflammation supports immunity and presumably tumor control, whereas chronic inflammation is 
associated with immunosuppression, tumor progression (Coussens et al., 2013), increased 
proliferation rates resulting in high mutation rates of some cells (Grivennikov et al., 2010; 
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Mantovani et al., 2008), angiogenesis and endothelial-to-mesenchymal transition (EMT) (Thiery, 
2002), suggesting that inflammation not only plays a role in the initial phase of tumor development, 
but also in metastasis formation. 
The strong correlation between chronic inflammation and cancer provides a rationale for using 
anti-inflammatory drugs in cancer prevention and therapy. For example, prophylactic use of aspirin 
and non-steroidal anti-inflammatory drugs (NSAIDs) reduced the incidence of colorectal, lung and 
esophagal cancer (Baron and Sandler, 2000). In addition, chronic low-dose aspirin intake because 
of a heart condition prevented the development of metastasis in several common cancers during 
and after trials (Rothwell et al., 2011; Rothwell et al., 2012). Because aspirin and NSAIDs interfere 
with many pathways including inflammation, clotting and others, the mechanistic basis for the 
beneficial action of such drugs in the context of cancer is currently not completely understood.  
Radiotherapy is a standard treatment for cancer patients and may represent a practical example of 
how acute and chronic inflammation differently impact on the tumor and its microenvironment. 
Radiotherapy induces DNA damage and ultimately cell death to which rapidly dividing cells, such 
as tumor cells, are more sensitive. Radiation-sensitivity of tumor cells is further enhanced by 
frequently occurring mutations in DNA-repair pathways (Begg et al., 2011).  
In the last years, it has become clear that radiotherapy modulates innate and adaptive immunity and 
that such responses are an integral part of the clinical response to radiotherapy (Apetoh et al., 2007; 
Burnette et al., 2011; Gupta et al., 2012; Sharma et al., 2013). Lee and colleagues used B16 
melanoma to show that single high-dose (20 Gy) or fractionated (3x 15 Gy) radiotherapy similarly 
delay tumor growth and depend on CD8+ T cells in the tumor (Lee et al., 2009). In the same model, 
radiotherapy induces increased expression of VCAM-1 on tumor endothelium favoring T cell 
infiltration (Lugade et al., 2005). The enhanced infiltration of CD8+ T cells into the tumor upon 
radiotherapy also depends on an increased expression of CXCL16 (Matsumura et al., 2008). Our 
lab demonstrated that the clinical efficacy of single high-dose radiotherapy depends on DCs 
maturation and activation of tumor-specific CD8+ T cells (Gupta et al., 2012). The secretion of high 
mobility group box 1 (HMGB-1) by dying tumor cells has been suggested as upstream mechanism 
for DC activation (Apetoh et al., 2007). Moreover, in vitro and in vivo models showed 
radiotherapy-mediated upregulation of MHC class I (Reits et al., 2006; Sharma et al., 2011) and 
tumor necrosis factor-alpha (TNF-α) (Hallahan et al., 1989). Our lab showed that radiotherapy 
upregulates several immune effector molecules and concomitantly downregulates immune 
suppressor molecules using paired biopsies from sarcoma patients (Sharma et al., 2013). Recently, 
it has been demonstrated in mice and humans that combination of two checkpoint inhibitors, anti-
CTLA-4 and anti PD-1/PD-L1, with radiotherapy give rise to a better immunity against the tumor, 
compred to radiotherapy alone (Twyman-Saint Victor et al., 2015). 
Systemic immunity against cancer is crucial to control of metastatic lesions and there is evidence 
that the combination of radiotherapy with immune stimulation may result in systemic tumor-
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specific immunity and control of distant, i.e. non-irradiated, lesions (abscopal effect) (Postow et al., 
2012; Verbrugge et al., 2014). All together, these finding in pre-clinical and clinical models 
demonstrate that radiotherapy elicits an immune response against the tumor that might be 
additionally potentiated by the combination with immunotherapy. 
Usually, patients are treated with external-beam fractionated radiotherapy given as daily low doses 
(1.5-2 Gy) over multiple weeks. Because this method allowed normal tissue to repair, it was 
established in the clinics at a time when radiation could not yet be targeted precisely to the tumor 
(Martin and Gaya, 2010). Advances in radiotherapy planning software, image guidance and 
treatment delivery have led to the development of hypo-fractionated radiotherapy, during which 
radiation is given as high doses (8-20 Gy) in fewer fractions. Clinical trials comparing the two 
radiation schemes showed that hypo-fractionated radiotherapy is characterized by a very accurate 
delivery of the dose, thus reducing the damage to the healthy tissue in the proximity of the tumor 
and consequently secondary symptoms. Moreover, this treatment has lower treatment cost and is 
not time-consuming. 
Currently, data comparing the clinical efficacy of both protocols are not yet available (Vaidya et 
al., 2010). The impact of hyper- and hypofractionated radiotherapy on inflammatory and immune 
responses has not been systematically studied, but we expect that hyper- but not hypofractionated 
radiotherapy will lead to a state of chronic inflammation. This may explain the apparent 
contradiction between our work and a recent paper by Elvington et al. (Elvington et al., 2014): 
Elvington et al. showed that inhibition of complement improved the efficacy of radiotherapy, 
whereas we found that local, radiotherapy-induced production of the anaphylatoxins C3a and C5a 
is essential to stimulation of protective immunity and efficacy of radiotherapy (Surace et al., 
2015b). Complement is a potent pro-inflammatory cascade that is activated in response to 
disturbance of homeostasis (Corrales et al., 2012; Markiewski et al., 2008; Nunez-Cruz et al., 
2012) and chronic complement activation may contribute to pathological conditions associated 
with chronic inflammation (Ricklin and Lambris, 2013). Whereas we used a single dose of 20 Gy, 
Elvington et al. used multiple low-dose irradiations on consecutive days, resulting in transient and 
chronic complement activation, respectively. Blockade of complement activation altogether by 
dexamethasone decreased the efficacy of single, high-dose radiotherapy (Surace et al., 2015b). 
These findings suggest that induction of an acute inflammatory response is an upstream event 
determining the therapeutic efficacy of radiotherapy. In stark contrast, hyper-fractionated 
radiotherapy delivered as daily fractions of 1.5 Gy or 7 Gy on five consecutive days resulted in 
chronic complement activation and increased infiltration of regulatory T cells in the tumor, but no 
protective tumor-specific immune response. We thus think that radiotherapy given in fewer 
fractions of higher dose with breaks in will result in (repeated) acute inflammatory responses that 
promote radiotherapy-mediated, tumor-specific immunity. Instead, conventional, hyper-
fractionated radiotherapy may induce a state of immunosuppressive, chronic inflammation.  
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In conclusion, we propose that eliciting acute inflammation in the tumor microenvironment boosts 
the tumor-specific immune response. Consequently, radiotherapy should be given as a single dose 
or as repeated doses with intervals (radiation holidays), which results in peaks of beneficial, acute 
inflammation. Such a schedule may result in a superior therapeutic responses compared to the 
conventional schedule of daily treatment (Surace et al., 2015a). 
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